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ABSTRACT 
 
SEMAPHORIN 3D SIGNALING IN CARDIOVASCULAR DEVELOPMENT 
Haig Aghajanian 
Jonathan A. Epstein 
 
Development of the heart is an intricate and complex process. Crucial to this process is 
vascular patterning and the signals that properly guide developing vessels. 
Consequences of improper patterning can be severe, including life-threatening 
congenital heart defects. In this dissertation, I investigate the role of the secreted 
guidance molecule semaphorin 3d (Sema3d) in cardiovascular patterning during 
development, and attempt to dissect the molecular mechanisms involved in Sema3d 
signaling. Using loss-of-function genetic experiments in mice, I model multiple forms of 
congenital heart defects such as total anomalous pulmonary venous connections, 
transposition of the great arteries, and congenital abnormalities of the coronary vessels. 
These mouse models are powerful tools, which I use to investigate the etiology and 
morphogenesis of these disorders. Critical to understanding these congenital defects in 
these models is precisely deciphering the cellular and molecular mechanisms involved. I 
show how Sema3d affects the motility, migration, and adhesion of endothelial cells 
through a process of cytoskeletal reorganization, and I identify multiple molecules in the 
Sema3d signaling pathway, including a novel holoreceptor comprised of the receptor 
tyrosine kinase ErbB2 and semaphorin receptor neuropilin 1. Elucidating the precise 
mechanisms of normal vascular development along with pathologic processes is a 
necessary step towards future interventions and possible therapeutics.   
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Chapter 1 : Introduction 
 
Summary 
 
In this dissertation I explore the role of signaling molecules in patterning the developing 
vasculature, and how improper vascular patterning can lead to congenital heart defects. 
In this introductory chapter I will discuss how the heart develops and the role vascular 
development plays in this process. I introduce general concepts regarding congenital 
heart disease and later in the chapter focus on three such disorders; total anomalous 
pulmonary venous connection discussed in Chapter 2, congenital abnormities of the 
coronary vessels discussed in Chapter 4, and transposition of the great arteries that I will 
discuss in Chapter 5. I also introduce the various signaling molecules I will investigate in 
later chapters and discuss what is known and not known in relation to cardiovascular 
patterning and development. Select passages, tables, and figures in this chapter were 
published in a review I co-authored for Cell Metabolism (Epstein, Aghajanian et al. 
2015).   
 
Cardiovascular development and congenital heart defects 
 
The heart is the first functional organ to form during embryogenesis. Heart development  
(Figure 1.1) begins with the migration of mesodermal precursors away from the primitive 
streak to form a bow-shaped structure called the cardiac crescent. This region can be 
	   	   2	   	   	  
	  
divided into the first heart field, which gives rise to the linear heart tube, and the second 
heart field, which gives rise to portions of the atria, the outflow tract and the right 
ventricle (Epstein 2010).  Initially, the heart consists of two layers; an inner endocardium 
and an outer myocardium. Subsequently, the myocardial layer expands and 
proepicardial progenitor cells migrate over the surface of the heart, contribute fibroblasts 
that invade the myocardial layer, and form the outermost epicardial layer. Complex 
asymmetric morphogenetic movements coupled with uneven growth rates contribute to 
looping and chamber formation.  A series of septation events results in a fully functional 
four-chambered heart integrated with systemic and pulmonary circulations (Epstein 
2010). This process is facilitated by neural crest cells, which migrate from the dorsal 
neural tube and invade the cardiac outflow tract (Kirby, Gale et al. 1983), contributing to 
the smooth muscle of the great vessels and which are required for innervation of the 
heart (Kirby and Stewart 1983).  
 
All together, the normal development of the heart involves the complex cooperative 
interplay of cell migration, proliferation, lineage specification, differentiation, as well as 
tight spatial and temporal transcriptional regulation. Any perturbations or abnormalities in 
these processes resulting in structural problems of the heart at the time of birth are 
known as a congenital heart defect (CHD) or congenital heart disease. Congenital heart 
defects are the most common major congenital defects occurring at a rate of 4-8/1,1000 
live births (Ferencz, Rubin et al. 1985). CHDs can be broadly classified as cyanotic and 
acyanotic. Cyanotic defects are so named because of the blue-grey skin color of affected 
neonates caused by the lack of oxygenated blood. This can be caused by right-to-left 
shunting (flowing) and the mixing of deoxygenated and oxygenated blood entering the 
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systemic circulation. Examples of cyanotic defects include persistent truncus arteriosus, 
transposition of the great arteries, and total anomalous pulmonary venous connections, 
which I will discuss later in this introduction and in Chapter 2. As the name would 
suggest, acyanotic defects do not result in decreased oxygen saturation of the blood and 
consist of left-to-right shunting of blood in the heart (atrial and ventricular septal defects; 
patent ductus arteriosus) or obstructive defects (pulmonary stenosis; aortic stenosis; 
coarctation of the aorta). Additionally, in Chapter 4 I will also discuss a related congenital 
abnormality of the coronary vasculature that is associated with CHD. 
 
The causes of CHD can be divided into two basic categories; genetic causes and non-
genetic causes. Examples of recognized non-genetic causes of CHD include infectious 
diseases (rubella)(Dewan and Gupta 2012), maternal exposure (alcohol, 
thalidomide)(Zhu, Kartiko et al. 2009), and environmental teratogens (dioxins, PCBs, 
pesticides)(Kopf and Walker 2009). Genetic causes of CHD include single gene 
mutations, chromosomal abnormalities, and copy number variations, and have been 
found to be autosomal dominant, autosomal recessive, as well as sex-linked (Fahed, 
Gelb et al. 2013). The earliest discovered genetic causes of were familial cases of CHD 
caused by autosomal dominant or sex-linked mutations, but were limited in resolution. 
More recently, animal models of CHD have greatly improved our understanding of the 
genetic, cellular, and molecular mechanisms involved in normal cardiovascular 
development as well as the etiology and morphogenesis of CHD (Fishman and Olson 
1997; Srivastava 2006; Evans, Yelon et al. 2010; Vincent and Buckingham 2010). The 
identification of causal genetic variations and understanding the pathobiology of CHD 
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are important steps towards future therapies and management of various congenital 
heart defects. 
 
Vascular Development 
 
Much of my thesis work pertains to the vascular component of cardiovascular 
development and the genetic, cellular, and molecular mechanisms involved in normal 
vascular patterning and disease. There are three main vessel systems that together 
make up the vascular system (Udan, Culver et al. 2013). The arterial system is made up 
of large arteries such as the pulmonary artery and dorsal aorta that carry blood away 
from the heart and branch off into progressively smaller diameter arteries, arterioles and 
capillaries. The venous system carries blood back to the heart, originating in capillary 
beds and moving through progressively larger diameter venules and veins. Finally, the 
lymphatic system collects and returns interstitial fluid from the body to the circulation. 
This vascular system begins to develop early in embryogenesis in tandem with the 
development of the heart.  
 
Vessels can develop in one of two ways. The process of blood vessels forming de novo 
from endothelial progenitors is termed vasculogenesis (Risau and Flamme 1995; 
Flamme, Frolich et al. 1997). Alternatively, a vessel that sprouts or branches from an 
existing vessel is termed angiogenesis (Risau 1997). Vascular endothelial progenitor 
cells known as angioblasts are derived from mesodermal cells during gastrulation. 
Angioblasts share a common progenitor with hematopoietic progenitors known as 
hemangioblasts that can give rise to both blood and endothelium (Murray 1932; Dzierzak 
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and Speck 2008). However, their fate is restricted once they have emigrated into extra-
embryonic tissue (extra embryonic ectoderm, yolk sac and allantois) and intra-embryonic 
tissues (embryonic ectoderm). In extra-embryonic tissue, these angioblasts aggregate to 
form blood islands, which are basic endothelial lined structures that are perfused with 
primitive erythrocytes (Sabin 1920). Fusion of blood islands leads to the formation of a 
honeycomb-shaped primitive capillary plexus. However, in intra-embryonic tissue, 
angioblasts aggregate to directly form vessels such as the dorsal aorta and cardinal 
vein, without a vascular plexus intermediate (Coffin and Poole 1988) (Figure 1.2).  
 
After the primitive vascular plexus along with dorsal aorta and cardinal vein are 
established, the vasculature undergoes growth and remodeling to form a mature 
circulatory system. Much of the growth of blood vessels at this point is through the 
process of angiogenesis, which again is the formation of new vessels from existing 
vessels. There are two types of angiogenesis; sprouting angiogenesis and 
intussusception (splitting) angiogenesis (Udan, Culver et al. 2013). Sprouting 
angiogenesis begins with signals to induce the formation of new vessels. The most well 
known inductive or pro-angiogenic signals are from the vascular endothelial growth 
factor (Vegf) family of ligands (Neufeld, Cohen et al. 1999; Coultas, Chawengsaksophak 
et al. 2005). Vessel induction is the first step in angiogenesis, and Vegf ligands along 
with their receptors coordinate with multiple signaling pathways, NOTCH signaling in 
particular, to induce, specify, grow, and fuse endothelial cells and vessels during 
angiogenesis (Adams and Eichmann 2010).  
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Concurrent with vasculogenesis and angiogenesis, endothelial cells and vessels begin to 
specify and commit towards an arterial, venous, or lymphatic fate. This specification is 
evidenced by the differential expression of marker genes or receptors on cells that are 
fated to one lineage versus another (Herzog, Guttmann-Raviv et al. 2005). This is seen 
in the exclusive expression of the receptor ephrin B2 on arterial endothelial cells and its 
cognate receptor EPH receptor B4 (Ephb4) on venous endothelial cells (Wang, Chen et 
al. 1998). These molecular markers are important tools in investigating vascular 
development and identity, which I utilize in my studies in Chapter 4. The heterogeneity in 
receptor makeup between arterial and venous endothelium can also help explain the 
sensitivity of certain endothelial cells to specific signals, and the divergent patterning and 
composition of these vessels even within close proximity. 
 
While vasculogensis, angiogenesis, and specification explain how endothelial cells and 
vessels come to be and grow, how the ultimate pattern of the vascular system is 
determined is a different question. Like the patterning of the nervous system, the pattern 
of the vascular system has been shown to guided by various signaling molecules 
(Adams and Eichmann 2010). These signaling molecules can direct endothelial motility 
and migration (Miao, Soker et al. 1999), remodel existing vessels through processes like 
pruning (Serini, Valdembri et al. 2003), and are crucial to proper pattern formation (Gu, 
Yoshida et al. 2005). My thesis work has been particularly interested in one such 
molecule, Semaphorin 3d (Sema3d), and the associated receptors/signaling molecules, 
which I will discuss later in this chapter and investigate in Chapters 2-4.  
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Pulmonary Vein Development and Disease 
 
As I will present and discuss in Chapter 2, my interest in congenital heart disease and 
cardiovascular patterning began with a phenotype we found in mice null for Sema3d. 
Mice lacking Sema3d develop abnormal connections of the pulmonary vein known as 
anomalous pulmonary venous connection (APVC). Normally, the pulmonary veins carry 
oxygenated blood from the lungs to the left atrium to be pumped to the left ventricle and 
the rest of the body by way of the aorta. Peripheral tissues utilize this oxygenated blood 
and deoxygenated blood is returned to the right atrium to be pumped back to the lungs 
via the right ventricle and pulmonary artery. When the pulmonary veins fail to connect to 
the left atrium and instead connect to the systemic circulatory system via the right atrium, 
a condition arises known as Anomalous Pulmonary Venous Connection (APVC)(Brody 
1942). APVCs can either be partial (PAPVC, some abnormal connections) or total 
(TAPVC, all pulmonary veins) and is a serious condition that can lead to cyanosis, heart 
failure, and death. Since fetal circulation bypasses the lungs until birth by the right-to-left 
shunting through the foramen ovale and ductus arteriosus, TAPVC does not affect the 
fetus until birth when they begin to use their lungs. As I introduced earlier, TAPVC is 
classified in the cyanotic category of congenital heart defects and is one of the so called 
“blue baby syndromes.” Interestingly, as many as 1 in 140 individuals have been 
reported to have PAPVCs upon post-mortem examination (Healey 1952; Kalke, Carlson 
et al. 1967). Although TAVPC is more rare, it is a much more serious condition with a 
mortality rate as high as 80% if left untreated (Burroughs and Edwards 1960). 
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Compared with our progressive understanding of the morphogenesis and molecular 
pathways involved in patterning of the outflow tract, which I will discuss later in this 
introductory chapter, very little is know about the molecular determinants and signals 
regulating the development pulmonary vein. Much of the studies investigating the 
development of the pulmonary veins have relied on descriptive anatomical analyses of 
staged embryos from human, mouse, and chick (Auer 1948; DeRuiter, Gittenberger-De 
Groot et al. 1995; Webb, Brown et al. 1998). Early pulmonary vein development is 
actually fairly conserved between vertebrate species, with some differences evident at 
later stages. For example, in the human, all four pulmonary veins have individual 
connections to the back of the heart, whereas in mouse, the pulmonary veins converge 
to form a common pulmonary vein before entering the left atrium (Sizarov, Lamers et al.). 
These descriptive analyses, however, failed to answer even some of the most basic 
questions about pulmonary vein development, namely where the pulmonary veins 
originate, and how do APVCs come about? Until very recently, there were conflicting 
hypotheses for these questions (Manner and Merkel 2007; Moorman and Anderson 
2007). The question of origin was partially answered in 2011 using a combination of 
high-resolution 3 dimensional imaging and molecular markers to determine cell identity 
(van den Berg and Moorman 2011). It was found that the pulmonary veins develop from 
a larger vascular plexus within the splanchnic mesoderm. Using our Sema3d null mice 
as a model, we attempt to resolve the controversy around the etiology and 
morphogenesis of TAPVC as I outline in Chapter 2.  
 
Furthermore, very little was known about the molecular mechanisms involved in these 
processes. What we did know was from familial genetic studies of TAPVC that have 
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suggested an autosomal dominant inheritance of the disorder with incomplete 
penetrance that maps to chromosome loci 4q12 (Bleyl, Ruttenberg et al. 1994; Bleyl, 
Nelson et al. 1995; Bleyl, Botto et al. 2006). Further analysis refined the location to an 
intergenic region between the gene for platelet-derived growth factor alpha (PDGFRA) 
and KIT. Blocking of Pdgfra by the receptor tyrosine kinase (RTK) inhibitor Imatinib 
(Buchdunger, Cioffi et al. 2000; Buchdunger, O'Reilly et al. 2002) in developing chick 
embryos resulted in TAPVC at a frequency of 25% (Bleyl, Saijoh et al. 2010). The same 
group examined the developing pulmonary veins of global Pdgfra knockout mice as well 
in temporally (E7.5) and spatially (dorsal mesocardium) restricted conditional knockouts. 
In all cases TAPVC was observed, albeit at a very low frequency. TAPVC is also 
associated with ANKRD1 gene overexpression. This is based on a chromosomal 
translocation or on a mutation in a putative PEST degradation motif in affected 
individuals (Cinquetti, Badi et al. 2008). 
 
While investigating the molecular mechanism by which Sema3d signaling patterns the 
pulmonary veins, the genetic evidence linking PDGFRA and TAPVC suggested shared 
pathways. As I will expand on later in this introduction, Sema3d is a secreted ligand and 
PDGFRA is a receptor tyrosine kinase. I hypothesized that PDGFRA may be a signaling 
receptor for Sema3d and sought to test that hypothesis, presented in Chapter 5, which 
turned out not to be the case. As happens frequently in science, my experimentation led 
me in an interesting new direction. I found that vascular inactivation of the Pdgfra gene 
led to a different cyanotic congenital heart defect, namely transposition of the great 
arteries (TGA), which I discuss in the next section. 
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Outflow Tract Development and Disease 
	  
The cardiac outflow tract (OFT) is the embryonic precursor to the great arteries, namely 
the ascending aorta and the pulmonary artery. In the embryo the OFT encompasses the 
arterial pole of the heart and connects the nascent ventricles of the heart with the aortic 
sac, a precursor to the ascending aorta and some pharyngeal arch arteries. A complex 
process of remodeling occurs to the outflow tract during development (Figure 1.1). The 
outflow tract starts off as a single endothelial lined myocardial tube, known as the 
truncus arteriosus, that will rotate and septate concurrent with the septation of the 
ventricles to ultimately give rise to a discrete aorta connecting to the left atrium and 
pulmonary artery connecting with the right atrium (Sugishita, Watanabe et al. 2004). Any 
perturbations to this process that lead to abnormal development results in a set of 
congenital heart defects known as conotruncal anomalies. Conotruncal anomalies 
include persistent truncus arteriosus (PTA) where the outflow tract fails to septate, 
double outlet right ventricle (DORV) where both the aorta and pulmonary artery arise 
from the right ventricle, Tetralogy of Fallot (ToF) which is a constellation of abnormalities, 
and transposition of the great arteries (TGA) in which the aorta incorrectly connects to 
the right ventricle and the pulmonary artery incorrectly connects to the left ventricle. All 
together, conotruncal anomalies account a significant portion of all congenital heart 
defects. 
 
Crucial to OFT development is the formation of the endocardial cushions populated by 
endothelial cells undergoing epithelial to mesenchymal transition (EMT) and migrating 
into the cardiac jelly, and invading cardiac neural crest cells migrating from the dorsal 
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neural tube through the pharyngeal arches (Sugishita, Watanabe et al. 2004). Ablation of 
cardiac neural results in various conotruncal defects (Kirby and Waldo 1995). 
Interestingly, transposition of the great arteries, which I discuss in the next section, is not 
one of the defects observed after neural crest ablation. 
 
Transposition of the Great Arteries (TGA) 
	  
Unlike our progressive understanding of the genetic, cellular, molecular, and 
morphologic processes of various conotruncal anomalies such as PTA, DORV, and ToF, 
very little is known of the etiology and morphogenesis of TGA (Unolt, Putotto et al. 
2013). There are a few genes that have been associated with this CHD in human 
(Goldmuntz, Bamford et al. 2002; Muncke, Jung et al. 2003; Karkera, Lee et al. 2007). 
Our lack of understanding of TGA is compounded by a paucity of animal models of this 
disorder. Currently there is only one descriptive study of TGA arising in mice null for the 
vascular extracellular matrix (ECM) molecule Perlecan (Costell, Carmona et al. 2002). 
Unfortunately, the only clue this study offers to the understanding of TGA is the presence 
of hyperplastic endocardial cushions. In Chapter 5, I describe a new animal model for 
TGA from endothelial inactivation of Pdgfra, and present additional clues to help 
decipher the morphogenesis and etiology of TGA. 
 
Coronary Vasculature Patterning 
 
A group of abnormalities related to congenital heart defects are congenital abnormalities 
of the coronary vessels. The coronary vessels serve to provide oxygen and nutrients to 
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the myocardium (heart muscle) and return deoxygenated blood and waste products back 
to the circulation. Early in mammalian development, simple diffusion is enough to 
provide for the thin myocardium, but as the heart grows and thickens, the coronary 
vasculature must develop to compensate. Failure of the coronary vasculature to properly 
develop can have severe consequences including death (Angelini 2007). 
 
Like the systemic circulation, coronary vessels are divided between arterial and venous. 
Coronary arteries receive oxygenated blood from the aorta and deliver it to the heart 
through smaller vessels and capillaries, and coronary veins return the blood to the 
pulmonary circulation via the coronary sinus, which feeds into the right atrium. The 
origins and development of the coronary vasculature are only now becoming apparent. 
Up until the late 1980s, the prevailing understanding of coronary vasculature 
development was that it came to be through the process of angiogenesis by sprouting off 
of larger vessels; the aorta for the coronary arteries, and the coronary sinus for the 
coronary veins (Hutchins, Kessler-Hanna et al. 1988). This notion was challenged when 
the coronary vasculature was observed to be present before the connections to the 
circulation were established (Bogers, Gittenberger-de Groot et al. 1989). Since that time 
there has been some controversy regarding the origins of the coronary vasculature. 
There is evidence for a number of sources for the endothelial cells that make up the 
coronary vasculature including the proepicardium (Katz, Singh et al. 2012), epicardium, 
endocardium, and sinus venosus (Red-Horse, Ueno et al. 2010; Chen, Sharma et al. 
2014). Endothelial cells migrate from these sources to encompass the heart and come 
together to form tube-like structures and a vascular plexus. Connections are formed 
when the arterial vascular tubes around the aortic trunk penetrate the aorta, and the 
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venous capillary beds form connections with the coronary sinus allowing for circulation of 
blood through the coronary vessels. 
 
The process by which the connections of the coronary vasculature to the circulation are 
made is not entirely clear. There is, however, some evidence of the mechanisms 
regulating coronary artery connections to the aorta. It has been shown that neural crest 
ablation results in anomalous origins of the coronary arteries (Hood and Rosenquist 
1992). Additionally, penetration of the coronary arteries into the aortic root requires Vegf 
family ligands (Tomanek, Ishii et al. 2006). In Chapter 4 I will describe what I believe to 
be the first evidence of the molecular mechanisms involved in coronary venous 
connections.  
 
Guidance Molecules in Cardiovascular Patterning 
 
The common theme for much of my thesis work on congenital heart disease has been 
elucidating the signals required for the vasculature to pattern correctly. Establishment 
and growth of blood vessels build a framework, but this vascular framework requires 
remodeling and guidance to form a functional vasculature. In this section I discuss the 
various signaling molecules that I have found to be involved in vascular patterning and 
congenital heart disease. These include ligands that signal to the developing 
vasculature, receptors residing on endothelial cells to receive such signals, and 
intermediate signaling molecules that transduce these signals.  
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Semaphorins 
	  
Semaphorins are a large family of secreted or membrane associated glycoproteins that 
are highly conserved both structurally and functionally throughout evolution from viruses 
to mammalians. Semaphorins and neuropilin receptors were initially identified as axon 
guidance molecules in the developing nervous system (Luo, Raible et al. 1993; He and 
Tessier-Lavigne 1997). Subsequently, semaphorins have been shown to function in a 
wide range of developmental, physiological and pathological processes outside of the 
central nervous system including lymphocyte activation, neural crest cell migration, 
vascular endothelial cell motility, bone growth, tumor angiogenesis and progression, lung 
branching morphogenesis and cardiovascular development (Kruger, Aurandt et al. 2005; 
Neufeld and Kessler 2008; Roth, Koncina et al. 2009; Neufeld, Sabag et al. 2012; Cora, 
Astanina et al. 2014). My work has focused on the role of Semaphorins in vascular 
patterning and congenital heart malformations (Table 1.1). 
 
Semaphorin signals act by juxtacrine, paracrine and autocrine mechanisms to modulate 
cellular behavior and are categorized into eight classes according to their structural 
features and species of origin (Kruger, Aurandt et al. 2005). Class 1 and 2 semaphorins 
are found in invertebrates, classes 3-7 are found in vertebrates and class 8 semaphorins 
are encoded by viruses (Figure 1.3). Though semaphorins differ in their amino acid 
sequence and overall structural characteristics, all members of the family contain a 
conserved ~500 amino acid “sema” domain located near the amino terminus of the 
mature protein. The sema domain is essential for receptor binding specificity and 
signaling (He and Tessier-Lavigne 1997; Koppel, Feiner et al. 1997). The sema domains 
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of several different semaphorins were recently characterized by mutagenesis, X-ray 
crystallography and three-dimensional modeling, which reveals that the sema domain is 
a variant of the seven blade β-propeller fold with overall structural similarities to the β-
propeller repeats of α-integrins (Siebold and Jones 2013).   
 
The different classes of semaphorins are characterized by class specific structural 
motifs. For example, classes 2-4 and 7 contain a single copy of an immunoglobulin-like 
domain, while class 5 semaphorins contain seven copies of a thrombospondin domain. 
All vertebrate and invertebrate semaphorins contain a PSI (plexin-semaphorin-integrin) 
domain that is required for homodimerization (Klostermann, Lohrum et al. 1998). Another 
important feature that differs between different semaphorin classes is the presence of 
membrane anchoring sequences. Classes 2 and 3 semaphorins are produced as 
secreted proteins, whereas classes 1, 4, 5 and 6 are intrinsic membrane proteins and 
class 7 semaphorins are membrane anchored proteins, which can be further processed 
into soluble proteins by proteolytic cleavage (Figure 1.3) (Siebold and Jones 2013).  
 
Class 3 Semaphorins 
 
I have been particularly interested in the role of class 3 semaphorins in vascular 
development. There is a growing body of literature implicating class 3 semaphorins in 
modulating endothelial behavior. Sema3a signals through Nrp1 on endothelial cells to 
inhibit proliferation, survival, migration, adhesion and capillary sprouting in aortic ring 
assays and can modulate retinal neovascularization after injury as well as vascular 
permeability (Miao, Soker et al. 1999; Acevedo, Barillas et al. 2008; Joyal, Sitaras et al. 
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2011). However, whether knockout of Sema3a causes abnormalities of murine vascular 
development remains controversial (Serini, Valdembri et al. 2003; Vieira, Schwarz et al. 
2007). Sema3b repels endothelial cells by binding to Nrp1, therefore functioning as an 
angiogenesis inhibitor (Varshavsky, Kessler et al. 2008). Sema3c induces endothelial 
cell proliferation, adhesion and migration (Banu, Teichman et al. 2006). As I will show in 
Chapter 3, Sema3d inhibits endothelial tube formation, adhesion, and motility through 
Nrp1 and PI3K/Akt dependent pathways.  Sema3f inhibits adhesion of endothelial cells 
to fibronectin and FGF-induced human umbilical vein endothelial cell proliferation and 
survival (Serini, Valdembri et al. 2003; Kessler, Shraga-Heled et al. 2004). Sema3g acts 
as a positive regulator of angiogenesis by stimulating endothelial cells and activating 
smooth muscle cells (Kutschera, Weber et al. 2011). In Chapter 3 I compare and 
contrast the effects of two of these Semaphorins, Sema3d and Sema3e, on endothelial 
cells. 
 
Neuropilins 
 
Two families of semaphorin receptors have been identified: plexins and neuropilins 
(Figure 1.3 and Tables 1.1, 1.2). Most membrane bound semaphorins bind directly to 
the plexin receptors. However this is generally not the case with (class 3) semaphorins, 
with the exception of semaphorin 3e (Sema3e), which require an initial interaction with a 
neuropilin co-receptor (Nrp1/Nrp2) to transduce their signal to plexin receptors (Gu, 
Rodriguez et al. 2003). Neuropilins are promiscuous co-receptors regarding both ligands 
and receptor partners that participate in a broad range of signaling pathways (Neufeld, 
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Kessler et al. 2002; Gu, Rodriguez et al. 2003; Hillman, Feng et al. 2011; Muders 2011; 
Rizzolio and Tamagnone 2011).  
 
The role played by neuropilin receptors in the vasculature is complicated by the fact that 
they can participate directly in Vegf signaling by heterodimerizing with Vegfr2 (Kdr) 
(Soker, Takashima et al. 1998; Kawasaki, Kitsukawa et al. 1999; Lee, Goishi et al. 
2002).  Nrp1 knockout embryos display a wide range of vascular defects, and 
overexpression of Nrp1 leads to excessive formation of blood vessels and capillaries 
(Kitsukawa, Shimono et al. 1995). Nrp1 is strongly expressed on the newly formed 
vasculature during wound healing and blocking of Nrp1 signaling reduces vascular 
density within the wound (Matthies, Low et al. 2002). Nrp2 deficient mice are viable 
(Chen, Bagri et al. 2000; Giger, Cloutier et al. 2000) but Vegf-induced retinal 
neovascularization is significantly compromised in Nrp2-/- mice (Shen, Samul et al. 
2004). Double Nrp1/Nrp2 knockout mice die as early as E8.5 and display a more severe 
vasculature phenotype than single knockouts suggesting partial functional redundancy 
(Takashima, Kitakaze et al. 2002). 
 
Abnormalities of the outflow tract have been described in Nrp1 knockout (Kawasaki, 
Kitsukawa et al. 1999) and endothelial-specific Nrp1 knockout mice (Gu, Rodriguez et al. 
2003). However, PTA is not observed in mice expressing a form of neuropilin-1 unable to 
bind class 3 semaphorins (Nrp1sema-) suggesting that sema-independent Nrp1 signaling 
in endothelial cells is essential for OFT septation (Gu, Rodriguez et al. 2003).  
Interestingly, Nrp1sema- mice on a Nrp2 null background do display PTA, suggesting 
functional redundancy.  Since Nrp1 can bind Vegf in addition to semaphorins, it is 
	   	   18	   	   	  
	  
possible that Vegf-dependent Nrp1 signaling modulates OFT development accounting 
for these findings.  However, Gu et al. recently reported the phenotype of a Nrp1 mutant 
mouse in which Nrp1 was mutated to specifically abolish Vegf binding.  The resulting 
Nrp1Vegf- mice survive to adulthood and do not display OFT defects (Gelfand, Hagan et 
al. 2014).  The relative influence of Vegf versus semaphorin signaling via neuropilins 
remains to be fully elucidated. 
 
Plexins 
 
The plexins are a conserved family of large proteins (~200 kDa), initially identified as cell 
surface molecules mediating cell adhesion (Ohta, Mizutani et al. 1995). Nine members 
have been identified in vertebrates that are divided into four classes: class A (plexin A1, 
A2, A3, A4), class B (plexin B1, B2, B3), class C (plexin C1) and class D (plexin D1) 
(Tamagnone, Artigiani et al. 1999). Unlike semaphorins, plexin architecture is conserved 
throughout the family. The extracellular domain of plexins contains one sema domain 
followed by three PSI and three IPT (Ig-like, plexin and transcription factor) repeats 
(Kruger, Aurandt et al. 2005). The sema domain acts as an autoinhibitory element 
modulating plexin activation in addition to its role in binding ligand (Figure 1.3). For 
example, plexin A1 (Plxna1) mutants lacking the sema domain are constitutively active 
suggesting that the sema domain is necessary to maintain Plxna1 in its basal inactive 
state (Takahashi and Strittmatter 2001). The IPT domain plays an important role in 
protein-protein interaction (Watarai, Sekine et al. 2008). 
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In Chapter 3 I investigate plexin D1 (Plxnd1) as a possible receptor for Sema3d. Plxnd1 
is expressed by endothelial cells during cardiovascular development (Gitler, Lu et al. 
2004; Zhang, Singh et al. 2009). Plxnd1 null pups and endothelial-specific Plxnd1 
knockouts die shortly after birth due with PTA, defective aortic arch arteries and 
ventricular septal defects (Gitler, Lu et al. 2004; Zhang, Singh et al. 2009).  Mutations of 
PLXND1 have been associated with isolated cases of truncus arteriosus in humans (Ta-
Shma, Pierri et al. 2013). Recent work by Worzfeld et al. demonstrates that transgenic 
mice harboring mutations in the GAP domain of Plxnd1 recapitulate the phenotype of 
Plxnd1 null mice suggesting that the GAP domain is essential for Plxnd1 signaling during 
cardiac development (Worzfeld, Swiercz et al. 2014).  Plxnd1 may interact with Nrp1 to 
transduce a Sema3c signal (Toyofuku, Yoshida et al. 2008) but the spectrum of Plxnd1 
ligands has yet to be fully defined, and the mechanism by which loss of Plxnd1 signaling 
in endothelium results in OFT defects remains obscure.   
 
ErbB Receptors 
 
Receptor tyrosine kinases (RTKs) are a group of single pass transmembrane 
glycoproteins that are involved in numerous biological processes including cell 
proliferation, differentiation, survival, death, and migration. RTKs consist of an 
extracellular ligand binding domain and an intracellular kinase domain. Binding of ligands 
to RTKs can transduce extracellular signals to a cell through the homo- or hetero-
dimerization of said receptors resulting in intracellular signaling. One such group of 
RTKs of particular interest to us is the epidermal growth factor receptor family also 
known as the ErbB family. The ErbB family of RTKs consist of four receptors; epidermal 
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growth factor receptor (EGFR/ErbB1/HER1), erb-b2 receptor tyrosine kinase 2 (ErbB2, 
HER2, neu), erb-b2 receptor tyrosine kinase 3 (ErbB3, HER3), and erb-b2 receptor 
tyrosine kinase 4 (ErbB4, HER4)(Riese and Stern 1998). The primary ligands for ErbB 
receptors are the EGF family of growth factors which include epidermal growth factor 
(EGF) and neuregulins 1 through 4 (NRG1-4), as well as transforming growth factor 
alpha (TGFA), amphiregulin (AR), heparin-binding EGF-like growth factor (HB-EGF), 
tomoregulin, epiregulin, epigen, betacellulin, and neuroglycan C (Massague and 
Pandiella 1993). These ligands have differential binding specificity to ErbB receptors. For 
example, EGF, TGFA, and AR preferentially bind to EGFR, whereas NRG1 and NRG2 
bind to ErbB3 and ErbB4. ErbB2 is the exception to this family as it has no direct ligand, 
but rather acts as the preferential co-receptor for the other ErbB receptors. This is 
evident in the ligand-induced interaction of ErbB2 and ErbB3. ErbB3 is unique in that it 
does not possess kinase activity, and ligand binding to ErbB3 can induce 
heterodimerization with ErbB2 and subsequent kinase activation of ErbB2 (Kim, 
Vijapurkar et al. 1998). The receptor ErbB2, also known as HER2, is best known for its 
role in cancer. ErbB2 is overexpressed in a subset of cancers, particularly breast 
cancers, that usually have a more aggressive progression (Yu and Hung 2000). 
However, ErbB2 has been successfully targeted in these cancers with a specific 
monoclonal antibody to ErbB2, trastuzumab, which has led to overall better outcomes.  
 
ErbB receptors have been shown to be important in development. Deletion of these 
genes results in various phenotype including cardiovascular ones. Global deletion of 
ErbB2 or ErbB4 in mice results in embryonic lethality around E10.5 from defects in 
cardiac trabeculation and nervous system development (Lee, Simon et al. 1995; Meyer 
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and Birchmeier 1995). Mice deficient in ErbB3 have defective valve formation (Erickson, 
O'Shea et al. 1997). And mice lacking EGFR have a range of phenotypes dependent on 
background and strain, from preimplantation lethality to valve malformations (Miettinen, 
Berger et al. 1995; Sibilia and Wagner 1995; Threadgill, Dlugosz et al. 1995; Chen, 
Bronson et al. 2000). Targeted studies examining the effects of ErbB2 loss in 
cardiomyocytes result in a phenotype of dilated cardiomyopathy (Crone, Zhao et al. 
2002; Ozcelik, Erdmann et al. 2002). More recently, ErbB2 has been shown to be critical 
in cardiomyocyte proliferation and regeneration and this pathway has become an 
attractive target for cardiac regenerative therapies (D'Uva, Aharonov et al. 2015). While 
the role of ErbB2 in cardiomycotes has been extensively studied, in Chapter 4 I explore 
an as of yet unappreciated aspect of the role ErbB2 during development. Specifically, I 
have found that ErbB2 is expressed in vascular endothelium during development and 
plays a critical role in coronary patterning.  
 
Pdgf Receptors 
 
Platelet derived growth factor receptors (Pdgfr) are receptor tyrosine kinases for the 
platelet derived growth factor (Pdgf) family of ligands. There are 2 Pdgfr molecules 
encoded by distinct genes, Pdgfr-alpha (Pdgfra) and Pdgfr-beta (Pdgfrb). Like the ErbB 
receptors, Pdgf receptors require dimerization to signal, which is dependent on ligand 
specificity. We became interested in Pdgfra because of evidence, discussed earlier in 
this introduction, suggesting an association with TAPVC.  
 
	   	   22	   	   	  
	  
Pdgfra is expressed in many cells of the heart including the multipotent cardiac 
progenitor cells during development (Van Den Akker, Lie-Venema et al. 2005; Bax, Lie-
Venema et al. 2009; Chong, Reinecke et al. 2013; Noseda, Harada et al. 2015). Global 
mutation of Pdgfra results in various cardiovascular malformations such as persistent 
truncus arteriosus, and double outlet right ventricle (Schatteman, Motley et al. 1995). 
These conotruncal abnormalities have been attributed to the role of Pdgfra in the neural 
crest (Richarte, Mead et al. 2007). Pdgf receptors have been investigated in multiple cell 
type important in heart development including cardiomyocytes (French, Creemers et al. 
2008), smooth muscle (French, Creemers et al. 2008), cardiac neural crest (Smith and 
Tallquist 2010), and epicardial cells. Surprisingly, very little is known about Pdgfra 
expression or function in endothelial cells. As I will show in Chapter 5, we find that 
Pdgfra is expressed in the embryonic vasculature, and conditional deletion of Pdgfra in 
endothelium leads to an entirely new phenotype not previously reported of transposition 
of the great arteries. 
 
Conclusions 
 
In this introductory chapter I have described how the heart and vasculature normally 
develop, and what we know about what happens when things go wrong. In the following 
chapters I use mouse genetic tools to further shed light on the etiology and 
morphogenesis of the congenital defects I discussed in this chapter. I will also 
demonstrate the interaction of many of the signaling pathways included in this chapter, 
and how these convergent signaling pathways are involved in cardiovascular patterning. 
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Table 1.1 
Mutation(s) Receptors 
or 
Ligands 
Stage of 
lethality 
Cardiovascular phenotypes 
and functions 
Refs. 
Semaphorins     
Sema3a-/- 
 
Plexin A1-
A4, D1, 
Nrp1-2, 
Vegfr2 
Postnatal  
 
Atrial defects, sinus 
bradycardia, 
lymphatic valve defects, 
vascular patterning defects. 
Sema3a inhibits 
angiogenesis. 
(Ieda, Kanazawa et 
al. 2007; Bouvree, 
Brunet et al. 2012; 
Jurisic, Maby-El 
Hajjami et al. 2012; 
Chen, Li et al. 
2013) 
Sema3b-/-  
 
Plexin A1-
A4, Nrp1-2, 
Vegfr2 
Viable No obvious cardiac defects. 
Sema3b inhibits 
angiogenesis. 
(Falk, Bechara et 
al. 2005) 
Sema3c-/- 
 
Plexin A2, 
D1, Nrp1-2 
Postnatal 
(varies 
with 
strain)  
 
PTA, VSD, aortic arch 
defects. Sema3c promotes 
angiogenesis. 
(Feiner, Webber et 
al. 2001) 
Sema3d-/- 
 
Nrp1 Viable  
 
Anomalous pulmonary 
venous connection, ASD. 
Sema3d repels pulmonary 
vein endothelial cells. 
(Katz, Singh et al. 
2012; Degenhardt, 
Singh et al. 2013) 
Sema3e-/- 
 
Plexin As 
(neuropilin 
dependent), 
Plexin D1  
Viable  
 
Vascular patterning defects. 
Sema3e restricts blood 
vessel growth to the 
intersomitic boundaries. 
Inhibits angiogenesis. A 61-
kDa Sema3e isoform 
promotes endothelial cell 
migration. 
(Gu, Yoshida et al. 
2005; Casazza, 
Finisguerra et al. 
2010) 
Sema3f-/- 
 
Plexin A3, 
A4, Nrp1-2 
Viable  
 
No obvious phenotype. 
Sema3f inhibits angiogenesis 
and lymphangiogenesis. 
(Sahay, Molliver et 
al. 2003) 
Sema3g-/- 
 
Nrp1-2 Viable 
 
Vascular remodeling defects. 
Sema3g promote 
angiogenesis. 
(Kutschera, Weber 
et al. 2011) 
Sema4a-/-  
 
Plexin B1-3, 
Plexin D1, 
Met, Erbb2 
Viable 
 
Enhanced angiogenesis in 
response to Vegf or 
inflammatory stimuli. Sema4a 
inhibits angiogenesis. 
(Kumanogoh, 
Shikina et al. 2005; 
Toyofuku, Yabuki et 
al. 2007) 
Sema4d-/- 
 
Plexin B1-2, 
C1, Met, 
Erbb2 
Viable 
 
Delayed atherosclerotic 
plaque formation due to 
impaired neovascularization. 
Sema4d promotes 
angiogenesis. 
(Zhu, Stalker et al. 
2009; Yukawa, 
Tanaka et al. 2010) 
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Sema5a-/- 
 
Plexin A3, 
B3, Nrp2, 
Met, Erbb2 
Viable or 
embryonic  
 
Defective cranial blood vessel 
remodeling. Sema5a 
promotes angiogenesis.  
(Fiore, Rahim et al. 
2005; Matsuoka, 
Chivatakarn et al. 
2011) 
Sema6a-/-  
 
Plexin A1, 
A2, A4, 
Vegfr2 
Viable 
 
 
Abnormal retinal vascular 
development. Sema6a 
promotes angiogenesis. A 
soluble form of Sema6a 
inhibits angiogenesis. 
(Segarra, Ohnuki et 
al. 2012) 
Sema6d-/-  
 
Plexin A1 Viable 
 
No obvious phenotype in 
mice. Sema6d modulates 
compact layer expansion and 
trabeculation in chick. 
(Toyofuku, Zhang 
et al. 2004; 
Toyofuku, Zhang et 
al. 2004; 
Takamatsu, 
Takegahara et al. 
2010) 
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Table 1.2 
Mutation(s) Receptors or 
Ligands 
Stage of 
lethality 
Cardiovascular phenotypes and 
functions 
Refs. 
Plexins     
Plxna1-/- Sema3a, 
Sema5a or 
5b, Sema6c 
or 6d 
Viable 
 
No obvious cardiac defects.  
Lymphatic valves are abnormal.  
(Takegahara, 
Takamatsu et 
al. 2006; 
Bouvree, 
Brunet et al. 
2012) 
Plxna2-/- Sema6a or 
6b 
Viable PTA and lack of aortic and 
pulmonary channel septation with 
incomplete penetrance. Double 
knockouts lacking Plxna2 and 
Plxna4 exhibit cardiovascular 
defects with higher penetrance.  
(Suto, Tsuboi 
et al. 2007; 
Toyofuku, 
Yoshida et al. 
2008) 
Plxna4-/- Sema6a or 
6b 
Viable Double knockouts lacking Plxna2 
and Plxna4 exhibit cardiovascular 
defects with higher penetrance. 
(Toyofuku, 
Yoshida et al. 
2008) 
Plxnd1-/- 
and 
Plxnd1ecKO 
Sema3a, 3c 
(neuropilin 
dependent) 
Sema3e, 4a 
(neuropilin-
independent) 
Postnatal  PTA, VSD, atrial defects, 
coronary artery and aortic arch 
defects. 
(Gitler, Lu et 
al. 2004; 
Zhang, Singh 
et al. 2009) 
Neuropilins    
Nrp1-/- 
 
 
Nrp1ecKO 
 
Nrp1-Sema 
Coreceptor 
for class 3 
semaphorins 
and others 
 
Embryonic 
E10.5-
12.5 
 
Perinatal  
 
Postnatal 
Various cardiac and vascular 
defects including PTA and aortic 
arch defects. 
 
PTA, BAE, AOC, VSD. 
 
BAE, VSD, lymphatic vessels and 
valve defects. 
(Kawasaki, 
Kitsukawa et 
al. 1999; Gu, 
Rodriguez et 
al. 2003) 
Nrp2-/- Coreceptor 
for class 3 
semaphorins 
and others 
Viable  Lymphatic vessel and capillary 
formation defect. 
(Giger, 
Cloutier et al. 
2000; Yuan, 
Moyon et al. 
2002) 
Nrp1-/-; 
Nrp2-/- 
Coreceptor 
for class 3 
semaphorins 
and others 
Embryonic 
(~E8.0)  
 
Vascular anomalies in both 
embryos and placenta. 
(Takashima, 
Kitakaze et al. 
2002) 
Nrp1Sema-; 
Nrp2-/- 
Coreceptor 
for class 3 
semaphorins 
and others 
Not 
reported 
PTA, BAE, AOC and VSD, no 
vascular defects reported. 
(Gu, 
Rodriguez et 
al. 2003) 
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Figure 1.1 Cardiac development 
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Figure 1.1 Cardiac development 
The heart originates from mesodermal cells in the primitive streak. During gastrulation, 
cardiac progenitors migrate to the splanchnic mesoderm to form the cardiac crescent.  At 
E7.5 in the mouse, the cardiac crescent can be divided into two heart field lineages 
based on differential gene expression and their respective contribution to heart, a first 
heart field (red) and a second heart field (yellow), which is located posteriorly and 
medially to the first heart field.  At E8.0, the linear heart tube is present. At E8.5, the 
looping is associated with uneven growth of cardiac chambers.  The outflow tract is at 
the arterial pole and the inflow tract and primitive atria are at the venous pole. By E9.5, 
the common atrium has moved superior to the ventricles and is separated by a distinct 
atrio-ventricular canal.  By E10.5, cardiac neural crest cells from the dorsal neural tube 
migrate via the pharyngeal arches to the cardiac outflow tract. Further cardiac 
development involves a series of septation events and myocardial trabeculation that 
result in a mature four-chambered heart integrated with the circulatory system depicted 
at E15.5. Figure from (Epstein, Aghajanian et al. 2015). 
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Figure 1.2 Schematic overview of mammalian vascular development 
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Figure 1.2 Schematic overview of mammalian vascular development. 
Vascular endothelial progenitor cells, known as angioblasts, are derived during 
gastrulation from mesodermal cells. These mesodermal cells have potential to give rise 
to both blood and endothelium. However, once they have emigrated into extra-embryonic 
tissue (extra embryonic ectoderm, yolk sac and allantois) and intra-embryonic tissues 
(embryonic ectoderm) their fate becomes restricted. These angioblasts aggregate to 
form blood islands in extra-embryonic tissue. Blood islands fuse to form a honeycomb-
shaped primitive capillary plexus. In intra-embryonic tissue, angioblasts aggregate and 
directly form the dorsal aorta and cardinal vein, without a vascular plexus intermediate. 
The primitive vascular plexus along with dorsal aorta and cardinal vein undergo 
remodeling to form a mature circulatory system. Lymphatic endothelial cells (LECs) are 
specified in embryonic cardinal veins at defined locations. Figure from (Epstein, 
Aghajanian et al. 2015). 
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Figure 1.3 Structure of semaphorins and their receptors 
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Figure 1.3  
Semaphorins are categorized into eight classes based on their structural features and 
species origin. Semaphorins are defined by the presence of a conserved “sema” domain 
near the N-terminus of the protein. Class 1 and 2 semaphorins are found in 
invertebrates, Class 3–7 in vertebrates and SemaV in certain viruses. Semaphorins are 
secreted (Sema2a-2b, Sema3a-3g and SemaV), membrane-bound (Sema-1a,1b, 
Sema4a-4g, Sema5a-5b and Sema6a-6d) or GPI-anchored proteins (Sema7a). Two 
distinct transmembrane receptor families have been identified as semaphorin receptors, 
plexins and neuropilins. Shown here are the eleven members of the plexin family, 
including the invertebrate plexins (Plexin A and Plexin B), and the two members of the 
neuropilin family. Generally, membrane-bound semaphorins (class 4–7) directly bind to 
plexins. However, most secreted semaphorins (class 3) require neuropilins (Nrp1 and 
Nrp2) as binding co-receptors to enable binding to plexins. Neuropilins provide binding 
specificity for the class 3 semaphorins, whereas plexins, which also contain a sema 
domain, serve as signaling partners. An exception to this rule is Sema3e; a secreted 
semaphorin that can directly binds to plexinD1. Sema7a, a GPI-anchored semaphorin, 
signals through integrin receptors. Vegfr2 can form a receptor complex with plexin A1 
that is required for Sema6d-mediated signaling in cardiac development. Class 4 and 5 
semaphorins are associated with plexin B1-3 receptors, and the receptor tyrosine 
kinases Met and Erbb2 can function as coreceptors with plexin Bs for certain class 4 
semaphorins. Protein domains are indicated: GAP, GTPase-activating protein; Ig-like, 
immunoglobulin like; PSI, plexin semaphorin integrin; IPT, Ig-like plexin transcription 
factors; CUB, complement C1r/C1s, Uegf, Bmp1; FV/VIII, coagulation factor V/VIII 
homology like; MAM, meprin like. Figure from (Epstein, Aghajanian et al. 2015).  
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Chapter 2 : Semaphorin 3d patterns the pulmonary veins 
  
My interest in the signaling molecules responsible for patterning the vasculature began while 
investigating the phenotype of the Sema3d null mice presented in this chapter. This work was 
done in collaboration with two postdoctoral fellows in our lab, Karl Degenhardt and Manvendra 
Singh. Much of this chapter was published as a letter in Nature Medicine (Degenhardt et al., 
2013) of which I was co-first author and contributed to almost all aspects of the project, including 
the writing and revisions. 
Summary 
	  
Total anomalous pulmonary venous connection (TAPVC) is a potentially lethal 
congenital disorder that occurs when the pulmonary veins fail to connect normally to the 
left atrium, allowing mixing of pulmonary and systemic blood (Brody 1942). In contrast to 
the extensive knowledge of arterial vascular patterning, little is known about the 
patterning of veins. Here we show that the secreted guidance molecule Semaphorin 3d 
(Sema3d) is crucial for normal patterning of the pulmonary veins.  Prevailing models 
suggest that TAPVC occurs when the midpharyngeal endothelial strand (MES), the 
precursor of the common pulmonary vein, fails to form at the proper location on the 
dorsal surface of the embryonic common atrium (Lucas, Amplatz et al. 1962; Lucas, 
Lock et al. 1988).  However, analysis of Sema3d mutant embryos shows that TAPVC 
occurs despite normal formation of the MES.  Rather, the maturing pulmonary venous 
plexus fails to anastomose uniquely with the properly formed MES, and forming 
endothelial tubes penetrate a boundary normally produced by Sema3d, resulting in 
aberrant connections.  Sequencing of SEMA3D in individuals affected with anomalous 
pulmonary veins identified a phenylalanine to leucine substitution that adversely affects 
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Sema3d function. These results identify Sema3d as a critical pulmonary venous 
patterning cue and provide experimental evidence for an alternate developmental model 
to explain abnormal pulmonary venous connections.   
Introduction 
 
Complete separation of systemic and pulmonary circulations occurs shortly after birth in 
humans.  In adults, the right ventricle pumps blood through the pulmonary arteries to the 
lungs, and oxygenated blood returns to the left atrium via the pulmonary veins. The left 
ventricle pumps blood to the systemic circulation where oxygen is utilized by peripheral 
tissues, and de-oxygenated blood is returned via the systemic veins to the right atrium.  
When some or all of the pulmonary veins improperly connect to the right atrium or to the 
systemic venous system, the clinical entities of partial anomalous venous connection 
(PAPVC) or total anomalous venous connection (TAPVC) result, respectively (Brody 
1942; Lucas, Lock et al. 1988; Seale, Uemura et al. 2010).  The result is a left-to-right 
shunt, with potential for cyanosis, increased volume load on the right heart, and heart 
failure.  PAPVC has been reported in up to one in 140 individuals (0.7%)(Adachi 1933; 
Hughes and Rumore 1944; Healey 1952; Kalke, Carlson et al. 1967). TAPVC is less 
common, but can result in severe cyanosis or congestive heart failure in infants. Left 
untreated, the mortality of TAPVC is 80% (Burroughs and Edwards 1960). 
 
In contrast to our progress in understanding the morphogenesis of the cardiac outflow 
tracts and great arteries, little is known about the molecular regulation of pulmonary vein 
formation.  Early development of the pulmonary veins is similar among vertebrate 
species including humans (Auer 1948). Subtle differences are evident at later stages.  
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For example, in humans the pulmonary vein is incorporated into the back wall of the left 
atrium and subsequent remodeling leaves four separate orifices (Sizarov, Lamers et al.), 
while mice have a single common pulmonary vein that enters the left atrium. Descriptive 
anatomic studies have suggested that pulmonary veins form initially as a dorsal 
evagination from the posterior wall of the embryonic atrium (Auer 1948) leading 
researchers to speculate that abnormal venous connections arise from absent or mis-
localized evaginations (Lucas, Amplatz et al. 1962; Lucas, Lock et al. 1988).  These 
studies have supported the teaching that TAPVC is caused primarily by defects in 
formation or maintenance of the midpharyngeal endothelial strand, the anlage of the 
pulmonary veins (DeRuiter, Gittenberger-De Groot et al. 1995; Keane, Lock et al. 2006; 
Moss and Allen 2008; Douglas, Jongbloed et al. 2010). Recently, use of high resolution 
3D reconstructions of avian embryos has helped to clarify that the pulmonary vein 
derives from a greater vascular plexus within the splanchnic mesoderm (van den Berg 
and Moorman 2011).  Incomplete remodeling of this plexus with failure of separation into 
distinct pulmonary and systemic vascular zones has been postulated to be a 
developmental mechanism that could result in APVC (van den Berg and Moorman 
2011). 
 
Human genetic studies of kindreds with TAPVC have provided evidence for autosomal 
dominant inheritance with incomplete penetrance and variable expression (Bleyl, Nelson 
et al. 1995; Bleyl, Botto et al. 2006), and genetic association has implicated loci on 
human 4q12 (Bleyl, Botto et al. 2006).  Candidate genes in that region include the 
vascular endothelial growth factor receptor gene KDR (kinase insert domain receptor) 
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and the gene encoding platelet derived growth factor receptor alpha (PDGFRA).  Indeed, 
a spectrum of inflow tract defects including a low incidence of TAPVC was noted in mice 
after inactivation of Pdgfra either globally or in dorsal mesocardium (Bleyl, Saijoh et al. 
2010).  Overexpression of the ANKRD1 gene is also associated with TAPVC based on a 
chromosomal translocation in one case or on a mutation in a putative PEST degradation 
motif (Cinquetti, Badi et al. 2008). The molecular mechanisms by which perturbations in 
these genes lead to anomalous connection of the pulmonary veins has yet to be 
described. 
 
Class 3 semaphorins are secreted molecules that primarily signal through neuropilin 
and/or plexin coreceptor complexes.  Semaphorins were originally identified as axon 
guidance molecules, but have since been implicated in multiple biological processes 
including cardiovascular patterning (Kruger, Aurandt et al. 2005; Kigel, Varshavsky et al. 
2008; Larrivee, Freitas et al. 2009).  For example, Semaphorin3e is required for 
intersomitic artery patterning (Gu, Yoshida et al. 2005) and Semaphorin3c is required for 
morphogenesis of the great arteries at the arterial pole of the heart (Feiner, Webber et 
al. 2001).  Sema3d is a related member of this class, that has been previously implicated 
in retinal ganglion cell axon patterning, and neural crest migration in zebrafish (Berndt 
and Halloran 2006; Sato, Tsai et al. 2006). 
Results 
 
To determine the role of Sema3d in cardiovascular development, we inactivated the 
gene by homologous recombination in embryonic stem cells (Figure 2.1 and (Katz, 
Singh et al. 2012)).  We created two distinct alleles, one of which resulted in truncation of 
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the protein after the 7th amino acid, and the other resulted in insertion of the coding 
sequence for a fusion of green fluorescent protein (GFP) and Cre recombinase at the 
initiating ATG.  In the latter case, GFP expression accurately recapitulates endogenous 
Sema3d expression (Katz, Singh et al. 2012).  The resulting phenotype of both modified 
alleles was identical.  Heterozygous mice appeared normal, while homozygous deficient 
animals exhibited abnormalities of pulmonary venous patterning.  Affected Sema3d–/– 
adult mice exhibited massively enlarged right atria and ventricles (Figure 2.2) consistent 
with a left-to-right shunt.  In control animals, the pulmonary veins were observed to 
connect to the left atrium, as expected (Figure 2.2a,c,e,f).  Anomalous connections to 
the coronary sinus (which connects to the right atrium), or directly to the right atrium, 
were noted in mutants (Figure 2.2b,d,g,h, Figure 2.3). Total or partial APVC was noted 
in 35% (14/36) of homozygous mutants.  The majority of affected animals displayed 
TAPVC (13/14).  TAPVC was associated with atrial septal defects in all of the affected 
Sema3d mutants. However, we did not notice any other structural defects and no 
abnormalities of laterality were observed in mutants. 
 
In order to determine when patterning defects were first evident, we examined  
Sema3d–/– murine embryos at progressively earlier stages.  At E17.5, optical projection 
tomography (OPT) imaging (Figure 2.4a,b) identified examples of abnormal connections 
of the pulmonary vein to the coronary sinus (3/8 mutants) (Figure 2.4b).  At E12.5 
(Figure 2.4c,d), abnormal pulmonary venous connections were also identified in 
Sema3d mutants (4/11 mutants) (Figure 2.4d).  Staining for expression of the 
endothelial marker Pecam1 (platelet and endothelial specific cell adhesion molecule) at 
E10.5 (Figure 2.4e,f) revealed the first signs of abnormalities of vascular patterning in 
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the region of the nascent pulmonary veins in mutants (4/10 mutants), which suggested 
the formation of abnormal venous connections in ectopic locations (Figure 2.4f).  At 
E9.5, abnormalities in endothelial patterning were not observed (Figure 2.4g,h and 
Figure 2.5).  Importantly, the midpharyngeal endothelial strand (labeled in Figure 2.4g,h 
and Figure 2.5) is easily identifiable at E9.5, and is unperturbed in Sema3d–/– embryos 
(0/9 mutants) (Figure 2.4g,h and Figure 2.5). This contradicts the widely held belief that 
failure of the formation of the normal pulmonary vein at the site of entry to the common 
atrium is the primary defect leading to TAPVC (2008; Moss and Allen 2008).  Rather, our 
findings suggest that patterning and connections of the pulmonary portion of the 
splanchnic venous plexus may be disrupted (see below). 
 
Class 3 semaphorins signal through receptor complexes containing Neuropilins (Zhou, 
Gunput et al. 2008).  We examined Sema3d expression as marked by GFP 
immunofluorescence in Sema3dGFPcre/+ mice, and Neuropilin-1 (Nrp-1) expression by 
immunofluorescence (Figure 2.6).  At E10.5, when patterning defects were first 
observed, Sema3d is expressed in the mesocardial reflections that form an anatomic 
boundary between the splanchnic mesoderm and the venous pole of the heart (Figure 
2.6a–c,h,i). Nrp-1 is expressed by the midpharyngeal endothelial strand at E9.5 and by 
pulmonary endothelial cells during early pulmonary vein patterning (Figure 2.6d, e and 
Figure 2.7). Nrp-1 has been reported to be arterial specific in chick (Herzog, Guttmann-
Raviv et al. 2005), though not in other systems (Evans, Yamaji et al. 2011; Pellet-Many, 
Frankel et al. 2011).  We performed co-immunofluorescence for Nrp-1 and Eph receptor 
B4 (Ephb4), a marker of venous endothelium. Nrp-1 and Ephb4 are co-expressed on 
pulmonary venous endothelium (Figure 2.6e,f).  
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To determine if Sema3d binds to pulmonary vein endothelium in vivo, we incubated 
cryosections from wildtype E10.5 embryos with conditioned media from HEK293T cells 
expressing alkaline-phosphatase tagged Sema3d (Sema3d-AP). Sema3d-AP binding 
was detected in the region of the nascent pulmonary veins (Figure 2.6g). No AP binding 
was detected on sections treated with control conditioned media (data not shown). The 
pulmonary venous plexus is normally constrained entirely to the region medial to the 
Sema3d expression domain and anastomoses with the midpharyngeal endothelial strand 
(Figure 2.6h).  However, in Sema3d mutants, numerous Pecam1 positive endothelial 
cells and tubes penetrate the lateral and caudal boundaries and intermingle with cells 
that would normally have been expressing Sema3d (identified by GFP 
immunohistochemistry in mutant specimens) (arrows in Figure 2.6i).  Quantification of 
serial confocal stacks confirms significantly greater overlap of GFP and Pecam1 
expression in mutants compared to controls (Figure 2.6j). The absence of Sema3d did 
not affect pulmonary endothelial cell proliferation or survival (Figure 2.8), and thus our 
data suggest that Sema3d regulates pulmonary vein patterning by directing pulmonary 
endothelial cell localization.  
 
Prior work has identified an avascular zone that forms within the splanchnic plexus to 
separate the pulmonary venous plexus from more caudal vascular structures associated 
with systemic veins (van den Berg and Moorman 2011).  Interestingly, Sema3d is 
expressed specifically within this avascular zone (Figure 2.9a–g) and this domain of 
Sema3d expression appears inappropriately vascularized in Sema3d mutants (Figure 
2.9h–k).  These findings are consistent with the hypothesis that failure of formation of 
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this avascular region could result in abnormal connections, as previously postulated (van 
den Berg and Moorman 2011). 
   
We sequenced the exons of SEMA3D in forty affected individuals (19 probands with 
TAPVC and 21 probands with PAPVC) and identified several variants (Table 2.1). While 
one of these variants, a c.193T>C missense which results in a serine to proline 
substitution (p.S65P), was found in both affected and control populations at 
approximately equal frequencies (1/20), a second c.1806T>A variant resulting in a 
phenylalanine to leucine substitution of amino acid 602 (p.F602L) was found only in an 
APVC affected individual and not in 80 control samples (Table 2.1 and Figure 2.10).  
The affected individual was Caucasian (as were 78 of 80 controls), had PAPVC with an 
associated VSD and had no evidence of laterality defects. Parental DNA was not 
available. This p.F602L variant is predicted to be possibly damaging by PolyPhen in 
silico analysis (Table 2.1), and the amino acid alteration is located in the 
Immunoglobulin (Ig)-like domain of Sema3d which has been shown to be important for 
both receptor binding and functional activity (Koppel, Feiner et al. 1997; Renzi, Feiner et 
al. 1999). Additionally, the p.F602L variant is absent from the 1000 genomes data set 
(1092 individuals) and the NHLBI Exome Sequencing Project (ESP) (13,000 
chromosomes) (Fu, O'Connor et al.) and was not found among the >800 chromosomes 
reported previously in which SEMA3D exons were sequenced for other reasons (Jiang, 
Turner et al. 2012; Luzon-Toro, Fernandez et al. 2013). 
 
In order to test the ability of wild type and variant Sema3d to bind to neuropilin receptors 
and to mediate guidance of endothelial cells, we generated alkaline phosphatase fusion 
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proteins. Binding to transfected Cos7 cells expressing Nrp-1 or Neuropilin-2 (Nrp-2) 
suggested that wild type and both Sema3d variants that we tested could bind to Nrp-1, 
although p.F602L bound with less affinity (Figure 2.11a and Figure 2.12). No significant 
binding to Nrp-2 was detected. Wild type Sema3d-AP was also found to bind to human 
umbilical vein endothelial cells (HUVECs) (Figure 2.13), which normally express Nrp-1 
(Evans, Yamaji et al. 2011; Pellet-Many, Frankel et al. 2011). This binding was 
significantly diminished with siRNA-mediated knockdown of Nrp-1 (Figure 2.14). 
 
To determine the endothelial guidance properties of Sema3d variants, HEK293 cells 
overexpressing either Sema3d or its variants were co-cultured with human umbilical vein 
endothelial cells (HUVECs). Time-lapse video analysis as well as micrograph 
quantitation confirms that Sema3d acts as a migratory repulsive cue in culture (Kigel, 
Varshavsky et al. 2008) (Figure 2.11b,c). Sema3d (p.S65P) repelled HUVECs similarly 
to wild type protein (Figure 2.11b,c); however, Sema3d (p.F602L) displayed markedly 
reduced repulsion activity (Figure 2.11b,c).  
 
To investigate whether Sema3d repulsion is mediated by Nrp-1, we blocked Nrp-1 
signaling by adding either soluble Nrp-1 or a Nrp-1-specific blocking antibody to the 
culture medium.  Both soluble Nrp-1 and Nrp-1-specific antibody significantly reduced 
HUVEC repulsion in response to Sema3d (Figure 2.11d,e). Although both arterial and 
venous endothelium express Nrp-1, recent studies have shown that cell responsiveness 
to semaphorin signaling can be mediated by differential expression of co-receptors as 
well as intracellular signaling factors acting downstream of receptors (Chauvet, Cohen et 
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al. 2007; Riccomagno, Hurtado et al. 2012). For example, Semaphorin 3e acts as a 
repellent signal on neurons expressing Plexin D1 but not Nrp-1, but acts as an attractive 
cue for neurons that express both (Chauvet, Cohen et al. 2007). Recently, Riccomagno 
et al. have shown that the effects of Sema3f in the central nervous system can be 
modulated by an intracellular Rac GTPase-activating protein, β2-chimaerin (β2Chn) 
(Riccomagno, Hurtado et al. 2012).  In the absence of β2Chn, Sema3f engagement of 
Nrp-2 can mediate axon repulsion, but β2Chn is required for axon pruning in response to 
Sema3f.  Thus, the downstream effects of Sema-Nrp interaction may be dictated by the 
expression or activities of receptors and downstream mediators. 
 
Discussion 
 
Taken together, these data implicate Sema3d as a repellent guidance molecule 
functioning to pattern the forming pulmonary venous vasculature (Figure 2.11f). We 
suggest that the absence of Sema3d-mediated repulsion allows pulmonary vasculature 
to stochastically form anomalous connections to adjacent systemic venous structures 
along a broad rostral-caudal domain, which could explain the morphologic APVC 
variability in Sema3d mutants and the diverse types of anomalous connections found in 
affected humans (van den Berg and Moorman 2011).  The lack of repulsion leads to a 
broad domain of abnormal endothelial sprouts, which may persist when they connect to 
a systemic vein and receive significant blood flow.  Hence, stochastic considerations 
may contribute to variation in patterning.  SEMA3D copy number variation has been 
linked to congenital heart defects (Silversides, Lionel et al. 2012), and the functional 
deficiencies of the p.F602L variant suggest a possible genetic contribution to this 
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common form of congenital heart disease in children, although further studies will be 
necessary to determine if SEMA3D mutations are sufficient to cause APVC in humans 
and to what degree sequence variants may contribute to this phenotype. Genetic 
variants or mutations in the genes involved in the Sema3d signaling cascade will be 
important future targets of study in individuals with congenital heart disease and 
pulmonary venous anomalies. Importantly, our data demonstrate a novel 
pathophysiology of APVC development that challenges the long held dogma about the 
etiology of this congenital disorder. Furthermore, these findings underscore the 
existence of specific morphogenetic pathways affecting subtypes of the vasculature and 
the importance of further investigation of the nature of vascular heterogeneity in 
development and disease. 
 
Materials and Methods 
 
Generation of Sema3d mutant mice: 
The generation and genotyping of Sema3dGFPcre knock-in mice are described elsewhere 
(Katz, Singh et al. 2012). Sema3d+/-  mice were made in a similar manner: ~20 kb of 
mouse genomic sequence surrounding exon 2 of the Sema3d gene (chr5:12438103-
12457989 of NCBI37/mm9 assembly) was recombineered into the pL253 plasmid (Katz, 
Singh et al. 2012). A FRTed PGKneo cassette was recombineered into exon 2 removing 
the splice donor of exon 2. The recombineering also placed stop codons 18 bp 
downstream of the ATG (Figure 2.1). Correctly targeted TL-1 ES cells were identified by 
PCR. Primers used for screening were Sema3d-F: 5ʼ-
ATGACTGGGCACAACAGACAATCGG-3ʼ and Sema3d-R: 5ʼ-
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TGAGGATGGGAACTGGTGGTATCAG-3ʼ (Figure 2.1b). Targeting was also confirmed 
by Southern blot (digest with EcoRV, probe with chr5:12,436,819-12,437,431, wild type 
band ~22 kb, mutant band ~12 kb) (Figure 2.1c). After blastocyst injection, germline 
transmission from chimeric males was confirmed by Southern and PCR as above, and 
subsequent generations by PCR with the following- Forward primer: 5ʼ-
ATTGCATCGCATTGTCTGAG-3ʼ (F1). Reverse primer: 5ʼ-
CTGCCACTGTCCTTCATTCC-3ʼ (R1). Sema3d-neo mice were crossed to beta-actin 
FLPe mice (Jackson Labs) to remove the neomycin cassette generating Sema3d+/-. 
Confirmation of FLPe excision of the cassette was performed by PCR. Forward primer: 
5ʼ-GAATGTTACTAAAGATAGCTAACTGACG-3ʼ (F2). Reverse primer: 
CTGCCACTGTCCTTCATTCC (R1) (Figure 2.1d, e). Sema3d expression in the adult 
(two months old) tissue was analyzed using forward primer: 5ʼ-
TGCTAGCAGGAAGGGTGAAC-3ʼ and reverse primer: 5ʼ-
TAGGTTAGCTTGAGTCTTGG-3ʼ (Figure 2.1f). Sema3d control and mutant embryos on 
a mixed sv129 and c57Bl/6 genetic background were analyzed at various developmental 
stages for APVC [8 controls and 8 mutants at E16.5-E17.5 (3/8 mutants were affected), 
16 controls and 11 mutants at E11.5-E12.5 (4/11 mutants were affected), 11 controls 
and 10 mutants at E10.5 (4/10 mutants were affected), 10 controls and 9 mutants at 
E9.5 (0/9 mutants were affected)].   
 
Micro computed tomography: 
MicroCT of iodine stained mouse tissue was performed as described (Degenhardt, 
Wright et al.). Briefly, tissue was fixed in 4% paraformaldehyde. After fixation, tissue was 
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washed in PBS and stained in 25% Lugolʼs solution prior to scanning. Reconstructed 
data sets were viewed in Osirix (www.osirix-viewer.com) for figures and movies. 
 
Optical projection tomography:  
OPT was performed on both unstained and whole-mount immunostained embryos in a 
Bioptonics OPT Scanner 3001M according to manufacturers instructions. Briefly, 
wholemount immunostained embryos were embedded in agarose and dehydrated in 
methanol, prior to clearing in benzyl alcohol – benzobenzoate (BABB) for scanning. 
Reconstructed data sets were viewed in Osirix (www.osirix-viewer.com) for figures and 
movies. 
 
Immunohistochemistry: 
Embryos were dissected in PBS and fixed immediately in 4% paraformaldehyde for 16-
20 h at 4 °C. Samples were washed with PBS, dehydrated in methanol series, and 
stored in 100% methanol at –20 °C. Immunofluorescent detection of GFP (Abcam- cat. 
no. AB6673, 1:100), PECAM1 (PharMingen- cat. no. 553370, 1:500), Ephb4 (R&D 
Systems- cat. No. AF446, 1:100), phospho-histone H3 (Cell Signaling- cat. no. 9706, 
1:200), and Nrp-1 (Abcam- cat. no. AB81321, 1:100) was performed on paraffin sections 
of paraformaldehyde-fixed embryos. TUNEL staining was performed using standard 
protocols. Whole-mount immunofluorescence studies of Sema3dGFPcre/+ and 
Sema3dGFPcre/GFPcre embryos for Pecam1 and GFP were carried out as described (Singh, 
Lu et al. 2011; Yokomizo, Yamada-Inagawa et al. 2012). Quantification of Pecam1 
staining overlapping GFP positive cells was done with Image J (imagej.nih.gov/ij) on 
stacks of confocal images. The ʻautoʼ setting was used for thresholding the green 
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channel (GFP) to make a mask extending approximately 10 µM around each labeled 
nucleus. The mask was then placed on the red (Pecam1) channel and measurements of 
integrated density were taken. 
 
Alkaline phosphatase binding assay:  
The Sema3d coding sequence was cloned into the pAPtag5 plasmid (Merte, Wang et 
al.) and transfected into HEK293T cells to produce conditioned media. Wild type and 
variant forms of Sema3d-AP were expressed and secreted at similar levels.  Binding to 
transfected (with either empty vector, Nrp-1 or Nrp-2) Cos-7 cells was performed as 
described (Gitler, Lu et al. 2004). Transfected cells were passaged into multiple wells 
prior to exposure to Sema3d-AP ligands in order to ensure equal expression of putative 
receptors in comparison groups.  Equal molar ratios (as calculated from AP enzymatic 
activity) of Sema3d-AP variants were incubated with transfected cells. Sema3d-AP 
protein binding to tissue sections was performed as previously described (Gu, Yoshida 
et al. 2005). Control (catalog no. AM4611) and Nrp-1 siRNA  (catalog no. AM16704) 
were purchased from Ambion. HUVECs were transfected with either control or Nrp-1 
siRNA (200 nM) using RNAiMAX (Invitrogen, catalog no. 13778030) for 48 h before 
Sema3d-AP binding. Nrp-1 knockdown was confirmed by RT-qPCR using Nrp-1 forward 
(5ʼ-TATTCCCAGAACTCTGCCC-3ʼ) and Nrp-1 reverse (5ʼ-
TGTCATCCACAGCAATCCCA-3ʼ) primers. Nrp-2 was used as control. Nrp-2 F primer: 
5ʼ-CCTGTGGTTGGATGTATGAC-3ʼ. Nrp-2 R primer: 5ʼ-GCAGTTCTCCAGTGGGACAT-
3ʼ. All expression values were normalized to β–actin. 
 
Endothelial cell repulsion assays:  
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Human umbilical vein endothelial cells (HUVEC lot #1023) and culture medium 
(Vasculife EnGS Complete Kit, Cat. no. LL-0002) were purchased from Lifeline Cell 
Technology and cultured according to the instructions of the manufacturer. HEK293T 
cells in 10 cm cell culture plates were transiently transfected to generate virus with 
either, pLOVE-Sema3d (WT), pLOVE-Sema3d (p.S65P), pLOVE-Sema3d (p.F602L), or 
GFP in addition to pMD.G and psPAX2 using FuGene transfection reagent. Lentiviral 
particles were collected after 24 and 48 h and concentrated using Millipore centrifugal 
filter units. The presence of virus was confirmed with Clontech instant lentiviral titer tests. 
HEK293 cells in 6 cm cell culture plates were subsequently infected with the harvested 
virus for a period of 48 h. After 48 h, the infected HEK293 cells were resuspended in 
media, washed, incubated with DiI solution, and plated on top of ~75% confluent HUVEC 
cells.  The mixture of cells was incubated for 24 h and observed with a Nikon Eclipse 
TE200 inverted microscope under a 20× objective. For Nrp-1 blocking experiment, 
soluble Nrp-1 (R&D systems, Cat. No. 566-N1, 5 nM) or a Nrp-1-specific antibody (R&D 
systems, Cat. No. AF566, 1 μg ml–1) was added to the medium. Digital images were 
captured and analyzed using ImageJ software. Cell-free areas surrounding infected cells 
were measured (n = 10–26 cells per group). 
 
Human genetics: 
40 probands with a primary or secondary diagnosis of Total or Partial Anomalous 
Venous Connection (21 probands with PAPVC and 19 probands with TAPVC) were 
ascertained through the Department of Cardiothoracic Surgery at the Childrenʼs Hospital 
of Philadelphia (CHOP) and voluntarily enrolled as part of an IRB approved protocol of 
informed consent.  PCR and sequencing primers were designed (using the ExonPrimer, 
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a Primer3 based algorithm available on the UCSC Genome Browser 
(http://genome.ucsc.edu/)) for the coding and flanking intronic regions of SEMA3D on 
Chromosome 7.   SEMA3D sequence annotation correlates to NM_152754.  The primers 
were synthesized by Integrated DNA Technologies (http://www.idtdna.com) and 
reconstituted at 200 uM.  Primer sequences, annealing temperatures and reaction 
conditions are available upon request.  PCR products were processed in the Nucleic 
Acids and Protein Core Facility at CHOP according to their standard Sanger sequencing 
protocol.  Sequence analysis was carried out using both Sequencher v4.9 (Gene Codes 
Corporation, Ann Arbor, MI) and MacVector (MacVector, Inc.) software.  All sequencing 
variants found were queried in the 1000 genomes database 
(http://www.1000genomes.org/) and run through SIFT (http://sift.jcvi.org/) and PolyPhen 
v2 (http://genetics.bwh.harvard.edu/pph2/) to predict potential pathogenicity.  Any 
variants not reported in the 1000 genomes database were first confirmed in the proband 
and then tested in a cohort of 80 ethnically matched control samples.  Due to the limited 
quantity of DNA available for each proband (<500 ng), a whole genome amplification 
(wga) reaction was required prior to PCR/sequencing.  Briefly, 10 ng of each probandʼs 
DNA was used as template in the commercially available GenomiPhi V2 DNA 
Amplification kit (Illustra, Inc.) and each reaction was carried out according to the 
manufacturerʼs protocol.  Agarose gel electrophoresis was used to assess the quality of 
the wga-DNA product.   The final amplification product stocks for each proband were 
diluted 1:20 and stored at –20 °C for use in downstream PCR/sequencing reactions.  
Wga-DNA product was used as template for all initial screening reactions of SEMA3D 
coding sequence.  Upon identification of a novel coding variant in a probandʼs wga-DNA 
sequence, the PCR/sequencing reaction was repeated using 20 ng of the original stock 
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DNA to confirm the variant existed in the original proband DNA sample and was not 
introduced by the wga reaction. 
 
Statistical Analysis: 
A two-tailed Studentʼs t-test or one-way ANOVA were used to analyze collected data that 
fulfilled the criteria. Significant differences in the ANOVA were further analyzed post-hoc 
by Tukeyʼs test for multiple comparisons (*P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant). All data expressed as the mean ? S.E.M.  
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Table 2.1 
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Figure 2.1 Targeting strategy and verification of germline transmission for 
Sema3d knockout allele 
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Figure 2.1 Targeting strategy and verification of germline transmission for 
Sema3d knockout allele 
(a) Homologous recombination arms (~10 kb each) flank the start of translation site in 
exon 2. Most of the coding region from exon 2 and the splice donor site are ablated and 
replaced by a neomycin resistance gene (neo) in the targeting construct. Frt sites (black 
triangles) flank the neo cassette. For negative selection, thymidine kinase (PGK-TK) is 
included. The starting ATG is left intact, but is followed by stop codons in all three 
reading frames (Stop × 3). EcoRV sites are located in the Sema3d locus outside the 
regions of the homologous recombination arms and an additional site is within the neo 
cassette. Orange arrows show the relative location of primers for PCR detection of 
recombined embryonic stem (ES) cells (Sema3d-F and Sema3d-R), the wild type allele 
(primers F1 and R1) and mutant allele (primers F2 and R1). (b) Representative PCR 
screening of targeted ES cell clones. A large (10.9 kb) band indicates a properly targeted 
clone. (c) Southern blot of ES cell DNA after EcoRV digestion shows wild type (~22 kb) 
band and an additional smaller (~12 kb) band in a correctly targeted clone. (d) Southern 
blot confirmation of germline transmission in mice (prior to excision of the neo cassette 
with Flp recombinase). (e) Representative PCR genotyping results for wild type, 
heterozygote and mutant mice after Flp recombination.  The expected PCR product size 
for the wild type allele is 927 bp and the expected size for the mutant allele is 985 bp. 
Proper excision of the neo cassette was confirmed by sequencing the PCR product. (f) 
Quantitative RT-PCR using primers for the deleted portion of the second exon confirms 
absence of the normal transcript in adult tissues. 
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Figure 2.2 Sema3d–/– mice have TAPVC 
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Figure 2.2 Sema3d–/– mice have TAPVC 
(a,b) Anterior views of wild type (a) and Sema3d–/– (b) hearts show severe cardiomegaly 
in the mutants due to right atrial (RA) and right ventricular (RV) dilation. (a right, b right) 
Pulmonary veins (PV) enter the left atrium (LA) in the wild type (a right) and the 
coronary sinus (CS) in the mutant (b right). (c,d) Photomicrographs of H&E sections 
showing normal connection to LA in wild type animals (c) and anomalous pulmonary 
venous connections to the CS in Sema3d–/– mice (d). (e–h) Volume-rendered microCT 
images (dorsal view) illustrate the pulmonary veins entering the posterior LA in control 
(e) and entering the CS in a newborn mutant (g). (f,h) Diagram of microCT images 
shown in (e,g) respectively. (i,j) M-mode echocardiograms through the ventricles of a 
control (i) and a Sema3d–/– (j) heart shows relative dilation of the RV in an adult 
Sema3d–/– mouse, and paradoxical septal wall motion indicative of right-sided volume 
overload. LA – left atrium,  LV – left ventricle, LU – lung, scale bar = 1 mm. 
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Figure 2.3 Anomalous connections of the pulmonary veins to the right atrium in 
Sema3d mutants 
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Figure 2.3 Anomalous connections of the pulmonary veins to the right atrium in 
Sema3d mutants 
(a) Multiplanar reformatted OPT image shows the pulmonary vein (PV) as it enters the 
right atrium (RA) in an E14.5 Sema3d mutant embryo. (b) H&E stained section of an 
adult Sema3d–/– heart shows a pulmonary vein entering the RA. CS – coronary sinus, 
RV – right ventricle, LV – left ventricle. Scale bar = 1 mm. 
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Figure 2.4 Pulmonary vein patterning defects are detected in Sema3d–/– embryos 
as early as E10.5. 
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Figure 2.4 Pulmonary vein patterning defects are detected in Sema3d–/– embryos 
as early as E10.5.  
(a,b) Volume rendered optical projection tomography (OPT) images of late stage (E17.5) 
wild type (a) and Sema3d–/– (b) heart-lung blocks show normal pulmonary vein (PV) 
connection to the LA in wild type, and connection to both the LA and CS in a Sema3d–/– 
specimen. (c,d) Serial multiplanar reformatted OPT images of E12.5 wild type (c) and 
Sema3d–/– (d) embryos show the course of the pulmonary vein from lung (LU) to the LA 
in the wild type and to the CS in the mutant. See Supplementary movie 3 for additional 
images. (e,f) Pecam1 immunofluorescence of E10.5 embryos shows the pulmonary 
vascular plexus coalescing into the pulmonary vein (PV), which runs between the 
mesocardial folds. In the wild type embryo (e) the PV remains near the midline, whereas 
the Sema3d–/– PV deviates laterally, and there are ectopic vessels (arrowheads) (f). 
(g,h) Pecam1 immunofluorescence at E9.5 shows no discernible abnormalities. Notably, 
the midpharyngeal endothelial strand (MES) forms normally. Panels (g,h) are also 
shown with adjacent sections in Figure 2.5. LA – left atrium, RA – right atrium, CS – 
coronary sinus, RL – right lung bud, LL – left lung bud, scale bar = 100 μm. 
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Figure 2.5 Vascular patterning appears normal in E9.5 Sema3d–/– embryos 
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Figure 2.5 Vascular patterning appears normal in E9.5 Sema3d–/– embryos.  
The top two rows show serial sections of Sema3d+/– and Sema3d–/– embryos from the 
level of the common atrium (left most panel) dorsally to the anterior cardinal veins (right 
most panels). Vascular patterning was visualized by Pecam1 immunohistochemistry. 
The lower two rows show multiplanar reformatted OPT images of Pecam1 wholemount 
immunostained embryos at roughly equivalent planes.  In addition, nine wholemount 
Pecam1 immunostained E9.5 embryos were examined by OPT (data not shown) with no 
defects detected. Importantly, the midpharyngeal endothelial strand (MES) was present 
in all embryos analyzed. Given, the prevalence of anomalous pulmonary veins in ~30% 
of Sema3d–/– mice, the number of embryos analyzed gives >95% chance of observing a 
defect at this stage if present. This argues against the long held view that failure of the 
development of the normal pulmonary vein is the inciting event leading to TAPVC. A- 
common atrium, V-ventricles, DA – dorsal aortae. Scale bar = 100 μm.  	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Figure 2.6 Sema3d-expressing cells form a boundary to restrict pulmonary 
endothelium 
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Figure 2.6 Sema3d-expressing cells form a boundary to restrict pulmonary 
endothelium.  
(a) Wholemount immunofluorescence for GFP in an E9.5 Sema3dGFPcre/+ embryo viewed 
by OPT. The 3D volume rendered image is digitally cut in cross-section. Sema3d 
expression marked by GFP (green) is in the mesocardial reflection and proepicardial 
organ (PEO). (b) Pecam1 immunofluorescence of E9.5 Sema3dGFPcre/+ embryo highlights 
the midpharyngeal endothelial strand (MES).  (c) GFP Immunofluorescence of E10.5 
Sema3dGFPcre/+ embryo at the level of the pulmonary vein (PV). (d) Adjacent section to (c) 
with Nrp-1 immunofluorescence . (e) Co-immunofluorescence for Nrp-1 (red) and Ephb4 
(green) at E11.5 shows that Nrp-1 expressing pulmonary vein (PV) endothelial cells also 
express Ephb4. (f) Nrp-1 and Ephb4 are co-expressed by endothelial cells of the 
cardinal veins (CV) but not the dorsal aorta (DA). (g) Sema3d-AP binding to E10.5 
transverse sections (g left). Adjacent sections were stained with Pecam1 (g center). 
Box shows area of forming pulmonary veins (PV). (h,i) 3D reconstruction of confocal 
imaged E10.5 Sema3dGFPcre/+ (h) and Sema3dGFPcre/GFPcre (i) embryos stained for Pecam1 
(red) and GFP (green). The 3D volume is digitally cut in cross section just above the PV 
and viewed from a cranial perspective. (h right) A close up of the boxed region in (h 
left). In mutants (i), Pecam1 positive endothelial cells (arrows) intermingle with GFP-
expressing cells. (j) Quantification of the amount of Pecam1 staining within 10 µm of 
GFP positive mesocardial cells in mutant and heterozygous embryos. *P  < 0.05 
(Studentʼs T-test). NT- neural tube, DA – dorsal aorta, RL – right lung bud, LL – left lung 
bud, scale bar = 100 μm for a–g, 25 μm for h,i.  
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Figure 2.7 Sema3d-expressing cells form a boundary to restrict pulmonary 
endothelium. 
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Figure 2.7 Nrp-1 is expressed by pulmonary vein endothelial cells during 
development.  
(a–l) Double immunofluorescence for Nrp-1 (green) and Pecam1 (red) at E9.5 (a–d), 
E10.5 (e–h) and E11.5 (i–l). (d,h,l) show higher magnifications of the boxed regions in 
(c,g,k), respectively. DA – dorsal aorta, MES – midpharyngeal endothelial strand, NT-
neural tube, RA-right atrium, RV-right ventricle, LV-left ventricle, V- ventricle, PV-
pulmonary vein, RL – right lung bud, LL – left lung bud. Scale bar = 100 μm.  
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Figure 2.8 Pulmonary vein endothelial cell proliferation and survival is not 
affected in Sema3d mutants 
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Figure 2.8 Pulmonary vein endothelial cell proliferation and survival is not 
affected in Sema3d mutants.  
(a,b) Immunofluorescence for phospho-histone H3 (pHH3) and Nrp-1 using E11.5 wild 
type and Sema3d–/– embryo sections at the level of the forming pulmonary veins (PV). 
(c) Quantification of pHH3 and Nrp-1 double positive cells was performed on eight 
sections from three individual embryos. (d,e) TUNEL assay for apoptotic cells was 
performed on adjacent sections. No significant differences in cell proliferation or 
apoptosis were observed. NS, not significant. Scale bar = 100 μm. 
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Figure 2.9 Sema3d expression creates an avascular zone 
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Figure 2.9 Sema3d expression creates an avascular zone. 
Coimmunofluorescence for Pecam1 (red) and GFP (green) in a Sema3dGFPcre/+ E10.5 
embryo shows an avascular region just caudal to the pulmonary vein (a–c). The 
pulmonary vascular plexus has been shown to separate from greater vascular plexus 
within the splanchnic mesoderm. The beginning of this separation occurs just caudal to 
the connection with the atria. Sagittal images of wholemount double stained embryos 
shows the area where this separation begins. An avascular zone overlaps with the 
region of expression from the Sema3d locus (green) just caudal to the vascular 
connection with the atria. (d–g) Off axis sagittal sections of a different control 
Sema3dGFPcre/+ embryo shows the region of GFP expression highlighted in the dashed 
oval. (g) Higher magnification of the area boxed in panel (f). (h–k) Mutant embryos, 
Sema3dGFPcre/GFPcre, at the same angle as (d–g), show incomplete separation of the 
pulmonary vein from the greater splanchnic plexus. This occurs where endothelial cells 
invaded the region that the Sema3d locus is active (as marked by GFP). (k) Higher 
magnification of the region boxed in (j). Scale bar = 100 μm. 
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Figure 2.10 Chromatogram of Sema3d variant. 
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Figure 2.10 Chromatogram of Sema3d variant. 
Forward and reverse sequence chromatograms of an APVC proband showing Sema3d 
(p.F602L) variant resulting in a phenylalanine to leucine substitution of amino acid 602, 
and a forward sequence chromatogram of a control individual. The individual bearing this 
variant was Caucasian and had PAPVC and a ventricular septal defect. NCBI reference 
sequence NM_152754 version NM_152754.2 GI: 41406085. 
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Figure 2.11 Sema3d binds to Nrp-1 and is capable of repelling endothelial cells.    
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Figure 2.11 Sema3d binds to Nrp-1 and is capable of repelling endothelial cells.   
(a) Wild type Sema3d and variants found in individuals with APVCs were tested in the 
context of alkaline phosphatase (AP) fusion proteins for binding to Nrp-1 and Nrp-2 
overexpressed in Cos-7 cells. Sema3f-AP was included as a positive control for binding 
to both neuropilins.  (b) Representative photomicrographs of diI (red) labeled HEK293 
cells transduced with Sema3d or control (GFP) lentivirus, and co-cultured with HUVECs. 
Repulsion results in a cell-free area (dotted yellow lines) surrounding HEK293 cells. (c) 
Quantification of cell free area surrounding HEK293 cells. Sema3d and Sema3d(p.S65P) 
display similar abilities to repel HUVECs. Sema3d(p.F602L) shows markedly reduced 
repulsion. GFP control transduced cells do not repel HUVECs. **P < 0.01 (One-way 
ANOVA between groups, P < 0.001; Post-hoc multiple comparisons, Tukeyʼs test). (d–e) 
Effect of soluble Nrp-1 (Nrp-1-Fc) (5 nM) and a Nrp-1-specific blocking antibody (Nrp-1 
ab) (1 μg ml–1) on Sema3d mediated endothelial cell repulsion. Blocking Nrp-1 signaling 
significantly reduced Sema3d mediated HUVEC repulsion. (f) Model depicting the role of 
Sema3d in pulmonary vein patterning.  *P < 0.05, **P < 0.01 (One-way ANOVA between 
groups P < 0.001, P < 0.01; Post-hoc multiple comparisons, Tukeyʼs test). Scale bar = 
100 μm  
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Figure 2.12 Sema3d(p.F602L) variant binds Nrp-1 expressing cells more weakly 
than wild type Sema3d. 
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Figure 2.12 Sema3d(p.F602L) variant binds Nrp-1 expressing cells more weakly 
than wild type Sema3d.   
(a) Photomicrographs of Nrp-1 transfected Cos-7 cells after binding to Sema3d-AP, 
Sema3d (p.S65P)-AP, Sema3d(p.F602L)-AP, or control alkaline phosphatase (AP). (b) 
Intensity of staining was quantified based on photomicroscopy after alkaline 
phosphatase color reaction on the basis of average integrated density using ImageJ. *** 
P < 0.001. Scale bar = 100 μm. 
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Figure 2.13 Sema3d(p.F602L) variant binds HUVECs more weakly than wild type 
Sema3d.   
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Figure 2.13  Sema3d(p.F602L) variant binds HUVECs more weakly than wild type 
Sema3d.   
(a) Photomicrographs of HUVECs after binding to Sema3d-AP, Sema3d (p.S65P)-AP, 
Sema3d(p.F602L)-AP, or control alkaline phosphatase (AP). (b) Intensity of staining was 
quantified based on photomicroscopy after alkaline phosphatase color reaction on the 
basis of average integrated density using ImageJ. *** P < 0.001.  NS, not significant. 
Scale bar = 100 μm. 
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Figure 2.14 Knockdown of Nrp-1 in HUVECs significantly reduces Sema3d-AP 
binding. 
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Figure 2.14 Knockdown of Nrp-1 in HUVECs significantly reduces Sema3d-AP 
binding. (a) Photomicrographs of HUVECs after binding to Sema3d-AP fusion protein. 
HUVECs were transfected with either control siRNA or Nrp-1 siRNA 48hrs before 
binding. (b) Intensity of staining was quantified based on photomicroscopy after alkaline 
phosphatase color reaction on the basis of average integrated density using ImageJ. *** 
P < 0.001 (c) Nrp-1 knockdown was confirmed by qRT-PCR. Scale bar = 100 μm. 
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Chapter 3 : Mechanisms of Semaphorin 3d signaling to endothelial cells 
 
In this chapter I continue my exploration of Sema3d signaling and mechanisms presented in 
Chapter 2. This work was done with the help of a medical student Connie Choi who visited our lab 
for a year. Much of this chapter was published as a cover article in the Journal of Biological 
Chemistry (Aghajanian et al. 2014). 
 
Summary 
	  
Class 3 semaphorins were initially described as axonal growth cone guidance molecules 
that signal through plexin and neuropilin coreceptors, and since have been established 
to be regulators of vascular development. Semaphorin 3e (Sema3e) was previously 
shown to repel endothelial cells and is the only class 3 semaphorin known to be capable 
of signaling via a plexin receptor without a neuropilin coreceptor. Sema3e signals 
through plexin D1 (Plxnd1) to regulate vascular patterning by modulating the 
cytoskeleton and focal adhesion structures. Recently, we have shown that semaphorin 
3d (Sema3d) mediates endothelial cell repulsion and pulmonary vein patterning during 
embryogenesis. Here we show that Sema3d and Sema3e similarly affect human 
umbilical vein endothelial cells (HUVECs) but through distinct molecular signaling 
pathways. Time-lapse imaging studies show that both Sema3d and Sema3e can inhibit 
cell motility and migration, and tube formation assays indicate that both can impede 
tubulogenesis. Endothelial cells incubated with either Sema3d or Sema3e demonstrate a 
loss of actin stress fibers and focal adhesions. However, the addition of neuropilin 1 
(Nrp1) blocking antibody or siRNA knockdown of Nrp1 inhibits Sema3d-mediated but not 
Sema3e-mediated cytoskeletal reorganization, and siRNA knockdown of Nrp1 abrogates 
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Sema3d but not Sema3e-mediated inhibition of tubulogenesis. On the other hand, 
endothelial cells deficient in Plxnd1 are resistant to endothelial repulsion mediated by 
Sema3e, but not Sema3d. Unlike Sema3e, Sema3d incubation results in 
phosphorylation of Akt in HUVECs, and inhibition of the Phosphoinositide 3-kinase 
(PI3K)/Akt pathway blocks the endothelial guidance and cytoskeletal reorganization 
functions of Sema3d but not Sema3e. 
 
Introduction 
 
Patterning of the vascular system requires coordinated temporal and spatial direction to 
the developing endothelium together with the ability of the endothelium to receive 
guidance signals. This is accomplished by a combination of secreted attractive and 
repulsive cues as well as cell-to-cell communications (Larrivee, Freitas et al. 2009). 
Disruption of these signaling pathways can result in improper endothelial cell guidance, 
developmental pathologies, and disease (Auerbach and Auerbach 1997). 
 
Semaphorins are a family of secreted and transmembrane signaling molecules that have 
been implicated in numerous and diverse biological processes (Kruger, Aurandt et al. 
2005). Originally discovered as axon guidance molecules (Luo, Raible et al. 1993), 
semaphorins have since been implicated in vascular patterning, tumor progression, and 
immune cell regulation (Bougeret, Mansur et al. 1992; Gitler, Lu et al. 2004; Neufeld and 
Kessler 2008). The class of secreted vertebrate semaphorins, class 3 (Sema3 proteins), 
has been shown to be particularly important in proper cardiovascular development (Gu 
and Giraudo 2013).  Loss of Sema3c in mice results in aortic arch malformations as well 
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as defects of outflow tract septation (Feiner, Webber et al. 2001). Sema3e is required for 
intersomitic vessel and aortic patterning (Gu, Yoshida et al. 2005; Meadows, Fletcher et 
al. 2012), and most recently we have demonstrated that Sema3d is necessary for proper 
pulmonary vein development and connection (Degenhardt, Singh et al. 2013).  
 
Several class 3 semaphorins can affect migration and motility of endothelial cells (Kigel, 
Varshavsky et al. 2008), and this function is what is believed to be responsible for 
Sema3 mediated cardiovascular development.  Canonical Sema3 protein signaling 
involves neruopilin/plexin heterodimeric receptors (Sharma, Verhaagen et al. 2012). With 
the exception of Sema3e, which can signal through Plxnd1 alone (Gu, Yoshida et al. 
2005), all other Sema3 proteins are thought to require either neuropilin 1 (Nrp1) or 
neuropilin 2 (Nrp2) co-receptors.  Although Sema3 proteins are capable of exerting both 
an attractive and repellent effect on neurons (Sharma, Verhaagen et al. 2012), in general 
their effect on endothelial cells appears to be of a repellent nature. The mechanism of 
endothelial repulsion in the case of Sema3e is a result of loss of focal adhesions and 
dismantling of the actin cytoskeleton (Sakurai, Gavard et al. 2010). The mechanisms of 
other Sema3 protein mediated endothelial repulsion remain poorly elucidated. 
 
In this study we show that Sema3d, like Sema3e, is capable of inhibiting endothelial cell 
motility, migration, and tube formation. Both of these Sema3 proteins accomplish these 
tasks by affecting cytoskeletal dynamics and cell adhesion. Interestingly, the 
mechanisms by which these two Sema3 ligands exert such similar effects on endothelial 
cells diverge at the level of receptor signaling. Unlike Sema3e, Sema3d does not require 
Plxnd1 for endothelial repulsion. And whereas Sema3d mediated inhibition of endothelial 
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tube formation and cytoskeletal rearrangements require Nrp1, Sema3e mediates these 
effects independently of Nrp1. We also observe distinct signaling pathways downstream 
of the receptors for these two Sema3 proteins. 
Results 
 
Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis. 
 To examine the effects of Sema3d and Sema3e on endothelial cell motility and 
migration, human umbilical vein endothelial cells (HUVECs) were incubated with equal 
concentrations (10nM) of Sema3d or Sema3e and live-imaged for 3 hours. A compilation 
of the tracks corresponding to individual endothelial cell migration paths showed that 
both Sema3d and Sema3e significantly decreased the total distance and the maximum 
displacement traveled by the cells compared to controls (Figure 3.1a, b). Moreover, 
HUVECs appeared to lose directional motility in the presence of both Sema3d and 
Sema3e, as they failed to migrate away from the point of origin as measured by 
maximum displacement normalized to total distance for each track. These data suggest 
that Sema3d and Sema3e mediate endothelial cell repulsion through inhibition of general 
and directed cell motility.  
 
We assessed how Sema3d and Sema3e affect the ability of HUVECs to form capillary-
like tubes on a basement membrane matrix. This assay allows us to investigate the 
effects of these Sema3 proteins on the endothelial cell migration and rearrangements 
necessary in angiogenesis. Both Sema3d and Sema3e significantly inhibited tube 
formation by HUVECs after 8 hours when compared with controls (Figure 3.1c, d). 
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These results demonstrate that both Sema3d and Sema3e similarly inhibit functional 
abilities of endothelial cells that are necessary for proper vascular development.   
 
Sema3d mediated endothelial repulsion does not require Plxnd1.   
In order to compare the chemotactic properties of Sema3d and Sema3e on endothelial 
cells, we employed a transwell migration assay. It was previously shown that endothelial 
cells are inhibited from migrating through a membrane towards a Sema3e gradient 
(Casazza, Finisguerra et al. 2010). To assess the necessity of Plxnd1 in this assay, 
endothelial cells were isolated from embryonic day 16.5 Plxnd1+/– and Plxnd1–/– mice. 
Both Sema3d and Sema3e were capable of inhibiting migration of Plxnd1+/– endothelial 
cells through a transwell membrane as compared with controls (Figure 3.2a). As 
expected, Sema3e was unable to inhibit migration of Plxnd1–/– endothelial cells (Figure 
3.2b, c). In contrast, Sema3d was able to inhibit endothelial migration even in the 
absence of Plxnd1 expression (Figure 3.2b, c). These results provide evidence of 
divergent signaling pathways for Sema3d vs. Sema3e despite similar functional 
activities. 
 
Sema3d and Sema3e cause loss of actin stress fibers and focal adhesions in endothelial 
cells.  
We next sought to investigate the cellular mechanisms by which these Sema3 proteins 
affect migration and motility. We compared the effects of Sema3d and Sema3e on actin 
stress fiber and focal adhesions in HUVECs. HUVECs were incubated with alkaline 
phosphatase (AP) tagged Sema3d, AP-Sema3e or AP alone in equal amounts as 
quantified by alkaline phosphatase activity. Both Sema3 proteins caused endothelial 
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cells to lose their cytoskeletal stress fibers (Figure 3.3a). The percent of cells with a loss 
of stress fibers was significantly more in both the Sema3d and Sema3d groups in as little 
as 15 minutes as compared with control (Figure 3.3b). Loss of actin stress fiber 
occurred at a similar rate in response to Sema3d vs. Sema3e, and more than 80% of the 
exposed cells had lost stress fibers by 60 minutes (Figure 3.3a, b). 
 
Concurrent with loss of actin stress fibers, focal adhesions (FAs), which adhere the 
cytoskeleton to the extra-cellular matrix, also decreased after exposure to Sema3d or 
Sema3e as visualized by the FA marker vinculin (Figure 3.3a). Quantification of the 
number of FAs per cell revealed a statistically significant decrease at 15 minutes with 
Sema3d (P < 0.01) or Sema3e (P < 0.01) and a continued decline thereafter when 
compared with controls (Figure 3.3c). A cell adhesion assay revealed that Sema3d and 
Sema3e were able to significantly inhibit HUVEC adhesion to a collagen matrix after 30 
minutes of incubation (Figure 3.3d). These results suggest that both Sema3d and 
Sema3e signal to modify the organization of the endothelial cell cytoskeleton and 
adhesion in a grossly similar manner. 
 
Sema3d mediated endothelial cell cytoskeletal reorganization and tubulogenesis is 
dependent on Nrp1.  
We examined the role of Nrp1 in Sema3d- and Sema3e-mediated cytoskeletal 
rearrangement in HUVECs by incubating cells with a blocking anti-Nrp1 antibody and 
either Sema3d or Sema3e. Visualization of actin and vinculin showed that blocking Nrp1 
inhibited Sema3d mediated but not Sema3e mediated cytoskeletal changes (Figure 
3.4a, b). Knockdown of Nrp1 in HUVECs using Nrp1 siRNA also showed that Sema3d, 
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but not Sema3e, requires Nrp1 to dismantle the cytoskeleton (Figure 3.4c). The ability of 
Sema3d to inhibit tubulogenesis was also dependent on Nrp1, while the activity of 
Sema3e in this assay was unaffected by Nrp1 knockdown (Figure 3.4d, e). Therefore, 
Sema3d and Sema3e engage endothelial cells via different receptor complexes to 
mediate similar effects on migration, tubulogenesis and cytoskeletal reorganization. 
 
Sema3d signals through the PI3K/Akt pathway.  
During a screen of intermediate signaling molecules involved in cytoskeletal dynamics, 
we found that Sema3d increased the phosphorylation of Akt in HUVECs (not shown). 
We confirmed this result and also determined that this effect was not seen in response to 
Sema3e (Figure 3.5a,b). Further examination revealed that Sema3d incubation 
increased Akt phosphorylation in HUVECs in a dose dependent manner (Figure 3.5c). 
To test whether the PI3K/Akt pathway was necessary for functional Sema3d signaling, 
we employed a transwell endothelial cell migration assay. Similar to the repulsion seen 
using Plexind1+/– endothelial cells (Figure 3.2a), both Sema3d and Sema3e were able to 
inhibit HUVECs from migrating through a transwell insert compared to vehicle control 
(Figure 3.5d). However, incubation with the PI3K inhibitor Wortmannin abrogated the 
ability of Sema3d to inhibit endothelial migration, but did not have an effect on Sema3e 
mediated inhibition (Figure 3.5d). 
 
To investigate whether the PI3K dependent repulsive action of Sema3d on endothelial 
cells was due to actin cytoskeletal regulation we visualized actin stress fibers in Sema3d 
or Sema3e incubated HUVECs in the presence or absence of the potent PI3K inhibitor 
Wortmannin (Figure 3.5e). As shown previously, Sema3d caused HUVECs to lose actin 
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stress fibers, but this response was greatly attenuated in the presence of Wortmannin 
(Figure 3.5f). In contrast, Wortmannin had no effect on Sema3e mediated actin 
reorganization.  
 
Discussion 
 
Our results indicate that Sema3d and Sema3e are capable of exerting similar effects on 
endothelial cells, but that these effects are mediated by distinct molecular signaling 
pathways. We show that Sema3d signals through Nrp1 and PI3K independently of 
Plxnd1, and Sema3e signals through Plxnd1 independently of Nrp1, while achieving 
similar functional endpoints.  It will be of interest to determine the details of the 
intracellular signaling pathways activated in response to various class 3 semaphorins, 
and at which points signaling via Sema3d and Sema3e converge.  In this regard, the 
details of how plexin and neuropilin receptors signal are only partially understood, and 
the complexity of Sema3 ligand-receptor interactions continues to emerge in the 
literature. While Sema3e can signal via Plxnd1 alone, the full description of the functional 
Sema3d receptor(s) are unknown and remain elusive, although our work indicates that 
Nrp1 is a necessary component of the Sema3d receptor in endothelial cells. We have 
been unable to detect binding of Sema3d to any of the plexins we have examined 
including Plexins A1, A2, A3, B2, and D1 (data not shown). In addition to plexin 
receptors, we have not detected binding of Sema3d to other candidate co-receptors 
including Pdgfra, Pdgfrß, Vegfr1, Vegfr2, or Vegfr3 (data not shown). 
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We demonstrate that Sema3d, but not Sema3e, induces Akt phosphorylation in HUVECs 
and requires PI3K signaling for endothelial repulsion. This is in contrast to the several 
class 3 semaphorins that negatively regulate Akt signaling. Sema3a, Sema3b, and 
Sema3f have all been shown to inhibit or decrease Akt phosphorylation in various cell 
types (Atwal, Singh et al. 2003; Chadborn, Ahmed et al. 2006; Guan, Villegas et al. 
2006; Potiron, Sharma et al. 2007; Castro-Rivera, Ran et al. 2008). Sema3e can inhibit 
Vegf mediated Akt phosphorylation in endothelial cells (Moriya, Minamino et al. 2010), 
but can also increase Akt phosphorylation in subicular neurons (Bellon, Luchino et al. 
2010). Our results provide an example of semaphorin mediated endothelial guidance 
requiring the PI3K/Akt signaling pathway. 
 
Although our results suggest that Sema3d and Sema3e produce similar effects on 
endothelial cells, it remains possible that unique functions exist for Sema3d or Sema3e 
that were not detected by our assays. Sema3e signaling, for example, can induce 
apoptosis in tumor endothelial cells (Casazza, Finisguerra et al. 2010). Sema3c 
promotes proliferation and inhibits apoptosis of mouse glomerular endothelial cells as 
well as affecting migration (Banu, Teichman et al. 2006). Sema3a inhibits cancer cell 
proliferation and causes cellular contraction (Sabag, Bode et al. 2012). Though Sema3b 
can induce similar morphologic contraction in these cells, it does not have the same 
effect on cell proliferation.  The effects of Sema3d and Sema3e may also depend upon 
the specific type of endothelial cells that are utilized.  Although our studies focused on 
HUVECs, it is becoming increasingly clear that important heterogeneity exists between 
endothelial populations (Yamamizu and Yamashita 2011). For example, arterial, venous 
and lymphatic endothelial cells differentially express neuropilin, Vegf and Notch 
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receptors.  Perhaps guidance queues mediated by Sema3 proteins are differentially 
interpreted by arterial, venous and lymphatic endothelium based in part upon receptor 
availability. It is worth noting that the primary defect resulting from Sema3d inactivation 
in the mouse is mis-patterning of the pulmonary veins (Degenhardt, Singh et al. 2013), 
while inactivation of Sema3e produces abnormalities of intersomitic arteries (Gu, 
Yoshida et al. 2005). 
 
In neurons, the cellular response to a given Sema3 protein may be dependent upon the 
receptor complexes that are expressed, and different receptors can produce opposing 
responses to the same ligand. During mouse neural development, for example, neurons 
that express both Plxnd1 and Nrp1 are attracted to Sema3e and migrate towards the 
signal (Chauvet, Cohen et al. 2007). In contrast, neurons expressing only Plxnd1 are 
repelled by Sema3e. Similarly in zebrafish, sema3d can act as a repellent signal to 
axons expressing nrp1A, and as an attractant to axons expressing both nrp1A and 
nrp2A (Wolman, Liu et al. 2004). Sema3e can also signal through a heterotrimeric 
receptor complex composed of Plxnd1, Nrp1, and Vascular endothelial growth factor 2 
(Vegfr2) to promote axonal growth (Bellon, Luchino et al. 2010). In contrast, Sema3e 
inhibits growth of axons expressing Plxnd1 only. The effects of Sema3 proteins are also 
modulated by variable expression of intracellular signaling components. In the central 
nervous system, for example, the ability of Sema3f to induce stereotyped axonal pruning 
of neurons originating in the dentate gyrus is dependent upon the presence of an intra-
cellular RacGTPase activating protein called β2-chimaerin which binds to the 
intracellular domain of Nrp2 and is activated by Sema3f binding (Riccomagno, Hurtado 
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et al. 2012). The ability of Sema3f to induce axon repulsion, however, does not require 
ß2-chimaerin. 
 
Nrp1, which we have shown is necessary for Sema3d repulsion of HUVECs, has also 
been demonstrated to serve as a subunit of a receptor for vascular endothelial growth 
factor (Vegf).  Sema3 competition with Vegf for neuropilin binding can inhibit the 
angiogenic effects of Vegf on endothelium (Parker, Linkugel et al. 2013). Furthermore, 
different members of the Sema3 family compete with Vegf with varying potency. We and 
others have recently shown that semaphorin-Plxnd1 activity can modulate VEGF 
signaling by inducing secretion of a soluble Vegf receptor (sFlt1)(Zygmunt, Gay et al. 
2011) and, conversely, Vegf can also act upstream of Plxnd1 to regulate its expression 
(Kim, Oh et al. 2011).  The result of Vegf and semaphorin integration modulates Notch 
signaling in tip and stalk cells of angiogenic sprouts and the combined actions of these 
signals contribute to determination of tip and stalk cell identity and the angiogenic 
response.  It seems likely that Sema3d and Sema3e will variably modulate and intersect 
with other important angiogenic and antiangiogenic pathways, including Vegf.  
 
The range and diversity of cellular effects in response to Sema3 proteins in different cell 
types speaks to the complexity of Sema3 protein-receptor signaling. We demonstrate 
that Sema3d and Sema3e can similarly affect endothelial motility and migration through 
distinct cellular mechanisms. Sema3e-Plxnd1 signaling in endothelial cells relies on the 
GTPase activating protein (GAP) activity of Plxnd1 to inactivate R-Ras and activate Arf6 
to modulate the cytoskeleton and cellular adhesion (Sakurai, Gavard et al. 2010). It will 
be of interest to investigate these pathways in Sema3d signaling in endothelial cells and 
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whether Sema3d requires a plexin co-receptor or an alternate signaling partner in 
association with Nrp1.  
 
Materials and Methods 
 
Cell Culture:  
HEK293T cells were cultured in Dubeccoʼs modified Eagleʼs media (DMEM) from Sigma 
with 10% fetal bovine serum (FBS). Primary human umbilical vascular endothelial cells 
(HUVECs) (lot #1023) were cultured in human endothelial cell culture media, VascuLife® 
EnGS (#LL-0002) (basal EnGS media, 0.2% EnGS, 5 ng/ml rh EGF, 50 µg/ml ascorbic 
acid, 10 mM L-glutamine, 1.0 µg/ml hydrocortisone hemisuccinate, 0.75 U/ml heparin 
sulfate and 2%) from Lifeline Cell Technology.  
 
Reagents and Antibodies: 
 Human recombinant Sema3e (#3239-S3-025), human recombinant Sema3d, and Anti-
neuropilin 1 antibody (#AF566) were obtained from R&D Systems. Anti-phospho- Akt 
(#4060), Anti-Akt (#9272), anti-β-actin (#4967), and Wortmannin (#9951) were 
purchased from Cell Signaling. Lipofectamine 2000 (Invitrogen) was used as the 
transfection reagent for HEK293T cells, Phallodin rhodamine (#PHDR1) was purchased 
from Cytoskeleton. Anti-vinculin antibody (#V9131) and CytochalasinD (#C2618) were 
obtained from Sigma Aldrich.  Prolong Gold Antifade Reagent with DAPI (#P36935) and 
Alexa Fluor 488 Goat Anti-mouse (#A11001) was obtained from Invitrogen. AP Assay 
Reagent A (#Q501) was obtained from GenHunter®. Coverslips and tissue culture plates 
were coated with type I rat tail collagen (#CB40236) from BD Biosciences. 
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Tubulogenesis assays were performed using Matrigel® Growth Factor Reduced 
(#354230, lot #2222781, endotoxin=3.4) from BD Biosciences.  
 
Production and Quantification of Conditioned Media: 
HEK293T cells were transfected with Sema3d-pAPtag5 plasmid, Sema3e-AP-pA6 or 
pAPtag4 plasmid in antibiotic-free DMEM with 10% FBS.  After 24 hrs, the media was 
changed to DMEM with 1% FBS and penicillin-streptomycin. After 48 hrs, the 
conditioned media was collected. YFP-PCDMA3.2 plasmid transfected into HEK-293T 
cells was used as a transfection control. A 50μl sample of the conditioned media was 
incubated at 65°C for 15 mins to inactivate endogenous AP activity. 50μl of AP Assay 
reagent A (2M diethanolamine, 1 mM MgCl, 1 mg/ml BSA and 24 mM p-
nitrophenylphosphate, pH 6.8) was added to the conditioned media and incubated at 
37°C for 10 min. 100μl 0.5N NaOH was added to stop the reaction. Absorbance was 
measured at 405nm. 
 
Microscopy and Image Analysis:  
For time-lapse experiments, HUVECs were cultured in a Nikon BioStation IM live cell 
recorder for 3 hours in the presence of 10nM recombinant Sema3d, 10nM recombinant 
Sema3e, or vehicle (PBS). Images were recorded with BioStation IM software. For 
immunofluorescence experiments, HUVECs were cultured on collagen-coated 
coverslips. They were treated with 10nM recombinant Sema3d, 10nM recombinant 
Sema3e, or vehicle (PBS). Alternatively, they were incubated with conditioned media 
containing equal quantities of Sema3d-AP, Sema3e-AP, or AP at 37°C where indicated 
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as measure by alkaline phosphatase activity.  The HUVECs were subsequently fixed 
with 3.7% formaldehyde for 10 min and permeabilized with 0.5% Triton for 5 min. Cells 
were stained with phalloidin rhodamine for 30 min, blocked with 2% w/v non-fat milk in 
dPBS for 60 min, incubated with anti-vinculin antibody for 60 min, and then Alexa Fluor 
488 anti-mouse IgG for 60 min. Coverslips were mounted with media containing DAPI 
stain, and the cells were visualized on a Nikon Eclipse80i microscope using NIS 
Elements software. Segmentation and quantification of focal adhesions were achieved 
using ImageJ software (Schneider, Rasband et al. 2012). A threshold was applied to 
vinculin stained images based on measurements of the mean gray value to exclude non-
fluorescent background pixels. “Analyze Particles” function was then used to count focal 
adhesions. Particles smaller than 1μm2 or with a circularity greater than 0.75 were 
excluded based on the sizes and shapes of previously published vinculin positive focal 
adhesions (Kim and Wirtz 2013). 
 
Matrigel Tubulogenesis Assay: 
Reduced growth factor Matrigel (289μl/well) was plated in the wells of a 24-well plate. 
Plate was incubated at 37°C for 30 min. HUVECs (6x104 cells/well) were plated and 
recombinant Sema3d (2μg/ml), Sema3e (2μg/ml), IgG (3.6μg/ml), Cytochalasin D 
(50ng/ml) or DMSO (2μl) was added to the appropriate well. The cells were incubated for 
8 hrs and visualized on an inverted Nikon Eclipse TE200 microscope using Capture 
Advanced software.  
 
RNA interference:  
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HUVECs were transfected with Lipofectamine RNAiMAX using Nrp1 pre-designed 
siRNA (Ambion, #4914) or Silencer Negative control siRNA #1 (Ambion, AM4611) in 
antibiotic-free media. The media was changed to complete HUVEC media after 24 hrs, 
and the cells were used at 48 hrs. 
 
Endothelial Isolation: 
Timed pregnant female from a Plxnd1 heterozygous mouse cross was sacrificed at 
embryonic day 16.5. Embryos were assessed for the presence of persistent truncus 
arteriosis (PTA) to identify nulls and subsequently genotyped for verification. Embryos 
(absent the head, heart, lungs, and liver) were minced and incubated with collagenase A 
(Sigma, C-0130). Single cell suspension was achieved by passing the cells through 
small gauge syringes and a 40µm nylon cell strainer. Cells were incubated with a 
PECAM antibody (BD Pharmigen, 557355) for 30 mins at 4°C, washed, incubated with 
Protein G Dynabeads (Life Technologies, 10003D), and washed again. Dynabeads were 
plated onto a fibronectin (Roche, 11051407001) in endothelial cell media. 
 
Transwell Migration:  
Transwell inserts (BD Biosciences, 353097) in triplicate were coated on the underside 
with 10µg/ml fibronectin (Roche, 11051407001) and placed in individual wells of a 24 
well plate containing either 10nM recombinant Sema3d, 10nM recombinant Sema3e, or 
vehicle (PBS) in DMEM. Endothelial cells were trypsinized, re-suspended in DMEM 
containing 0.2% BSA (Gemini, 700-101P), and 105 cells were seeded in each insert and 
allowed to migrate for 5 hours. For inhibitor experiments, the cells were re-suspended in 
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media containing either Wortmannin (1 μM) or a DMSO vehicle control when seeded in 
the inserts. The migrated cells were fixed in 4% paraformaldehyde for 2 mins, 
permeabilized in methanol for 20 mins, and stained with giemsa (Sigma, GS-500) for 25 
mins. Cell that did not migrate were scraped from the inside of the insert with a cotton 
swab. Three high power fields of each insert were imaged using an Olympus MVX10 
microscope and quantified using ImageJ. 
 
Cell Adhesion Assay: 
Collagen I coated cell adhesion plates (Cell Biolabs, CBA-052) were allowed to warm to 
room temperature for 10 minutes. HUVECs were re-suspended in DMEM containing 
0.2% BSA and either 10nM Sema3d, 10nM Sema3e or a vehicle control. 3x105 cells 
from each condition were transferred to individual wells and incubated for 30 minutes. 
Non-adherent cells were washed away, the remaining cells stained and extracted, and 
the optical density was measured at 560 nm. 
 
Western Blotting: 
Blots were probed with anti-phospho-Akt (1:2000), anti-Akt (1:1000), or anti-β-actin 
(1:1000) as per manufacturerʼs instructions. Visualization was achieved using ECL Prime 
(GE Life Sciences). Quantification of individual band intensity was performed using 
ImageJ. 
 
Statistical Analysis:  
One-way analysis of variance (ANOVA) was used to assess statistical differences 
between groups. Significant ANOVA results were further analyzed by Tukeyʼs multiple 
	   	   94	   	   	  
	  
comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant. All data is 
represented as the mean ± standard error of the mean (SEM).  
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Figure 3.1 Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis. 
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Figure 3.1 Sema3d and Sema3e inhibit endothelial cell motility and tubulogenesis.  
(a) Tracks represent the migration paths of individual HUVECs incubated with Sema3d, 
Sema3e, or vehicle control for 3 hours. (b) Quantification of total distance (µm) and 
maximum displacement (µm) of HUVECs in each condition. ***P < 0.001 (one-way 
ANOVA between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test). (c) 
Photomicrographs of HUVECs seeded in Matrigel and incubated with Sema3d, Sema3e, 
Cytocholasin D, or vehicle control for 8 hours. Cytochalasin D is used as a positive 
control for inhibition of tubulogenesis. (d) Quantification of the number of tubules formed 
per high power field. **P < 0.01, ***P < 0.001 (one-way ANOVA between groups P < 
0.001; post-hoc multiple comparisons, Tukeyʼs test, n = 9).  Scale bars = 50 µm (a), 1 
mm (c). 
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Figure 3.2 Sema3d inhibits endothelial migration independent of Plxnd1 
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Figure 3.2: Sema3d inhibits endothelial migration independent of Plxnd1.  
(a) Graph representing the percentage of Plxnd1+/– endothelial cells that migrated 
through a porous transwell insert in the presence of Sema3d or Sema3e compared with 
vehicle control. ***P < 0.001 (one-way ANOVA between groups P < 0.001; post-hoc 
multiple comparisons, Tukeyʼs test, n = 3). (b) Graph representing the percentage of 
Plxnd1–/– endothelial cells that migrated through a porous transwell insert in the 
presence of Sema3d or Sema3e compared with vehicle control. **P < 0.01, ns = not 
significant (one-way ANOVA between groups P < 0.001; Post-hoc multiple comparisons, 
Tukeyʼs test, n = 3). (c) Photomicrographs of stained endothelial cells that migrated 
through a transwell membrane in the presence of vehicle (left), Sema3d (center), or 
Sema3e (right). Scale bar = 100 µm. 
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Figure 3.3 Sema3d and Sema3e induce loss of actin stress fibers and down-
regulate focal adhesion complexes. 
  
	   	   100	   	   	  
	  
Figure 3.3 Sema3d and Sema3e induce loss of actin stress fibers and down-
regulate focal adhesion complexes.  
(a) HUVECs were incubated with alkaline phosphatase-tagged Sema3d, Sema3e, or 
alkaline phosphatase alone (AP) as a control for 0, 15, 30, 45 and 60 mins and stained 
for F-actin (red) and vinculin (green). (b) Quantification of the percentage of HUVECs 
displaying loss of actin stress fibers at each time point. (n=60 cells per condition) (c) 
Quantification of the number of vinculin units per HUVEC at each time point. (n=10 cells 
per condition) (d) Percentage of HUVEC adhesion to collagen I after a 30-minute 
incubation with Sema3e, Sema3d, or a vehicle control as quantified by a colorimetric 
assay. *P < 0.05, ***P < 0.001 (one-way ANOVA between groups; post-hoc multiple 
comparisons, Tukeyʼs test, n = 5). Scale bars = 50 µm (smaller bar), 5 µm (larger bar).  
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Figure 3.4 Sema3d-meidated but not Sema3e-mediated cytoskeletal 
reorganization and inhibition of tubulogenesis is dependent on Nrp1 
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Figure 3.4 Sema3d-meidated but not Sema3e-mediated cytoskeletal 
reorganization and inhibition of tubulogenesis is dependent on Nrp1.  
(a) HUVECs were exposed to Sema3d, Sema3e, or vehicle control with or without an 
anti-NRP-1 blocking antibody for 60 min and subsequently stained for F-actin (red) and 
vinculin (green). (b) Quantification of the percentage of HUVECs displaying absence of 
actin stress fibers in each condition. ***P < 0.001 (one-way ANOVA between groups P < 
0.001; post-hoc multiple comparisons, Tukeyʼs test, n=60 cells per condition). (c) 
Quantification of the percentage HUVECs with loss of actin stress fibers after Nrp1 or 
control siRNA transfection incubated with Sema3d, Sema3e, or vehicle control. ***P < 
0.001 (one-way ANOVA between groups P < 0.001; post-hoc multiple comparisons, 
Tukeyʼs test, n=60 cells per condition), and Western blot of Nrp1 protein expression in 
HUVECs after siRNA mediated knockdown. (d) Photomicrographs of HUVECs after 
Nrp1 or control siRNA-mediated knockdown, seeded in Matrigel, and incubated with 
Sema3d, Sema3e, or vehicle control for 8 hours. (e) Quantification of the number of 
tubules formed per high power field. ***P < 0.001 (one-way ANOVA between groups P < 
0.001; post-hoc multiple comparisons, Tukeyʼs test, n =9). Scale bar = 5 µm (a), 1 mm 
(d). 
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Figure 3.5 Sema3d signals through PI3K/Akt to repel endothelial cells via actin 
cytoskeletal reorganization. 
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Figure 3.5: Sema3d signals through PI3K/Akt to repel endothelial cells via actin 
cytoskeletal reorganization.  
(a) Western blot for phospho-Akt (S473) of HUVECs treated with Sema3d, Sema3e, or 
vehicle for 5 minutes. (b) Quantification of Akt phosphorylation normalized to total Akt of 
HUVECs incubated with 10nM of Sema3d, Sema3e, or a vehicle control for 5 minutes. 
**P < 0.01, ns = not significant (one-way ANOVA between groups P < 0.01; post-hoc 
multiple comparisons, Tukeyʼs test, n = 3). (c) Western blot for phospho-Akt (S473) of 
HUVECs treated with increasing doses of Sema3d for 30 minutes. (d; top) Graph 
representing the percentage of HUVECs that migrated through a porous transwell insert 
in the presence of Sema3d or Sema3e compared with vehicle control. ***P < 0.001 (one-
way ANOVA between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test, n 
= 3). (d; bottom) Graph representing the percentage of HUVECs that migrated through 
a porous transwell insert towards media containing Wortmannin and either Sema3d or 
Sema3e compared with vehicle control. *P < 0.05, ns = not significant (one-way ANOVA 
between groups P < 0.001; post-hoc multiple comparisons, Tukeyʼs test, n = 3). (e) 
HUVECs were incubated with Sema3d, Sema3e, or vehicle control with or without 
Wortmannin (1 μM) for 30 min and subsequently stained for F-actin (red) and vinculin 
(green). (f) Quantification of the percentage of HUVECs displaying absence of actin 
stress fibers in each condition. ***P < 0.001 (one-way ANOVA between groups P < 
0.001; post-hoc multiple comparisons, Tukeyʼs test, n=60 cells per condition). Scale bar 
= 5 µm. 
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Chapter 4 : Endothelial ErbB2 as a semaphorin receptor in coronary 
development 
 
Summary 
 
Recent work has elucidated the cellular origins and molecular mechanisms that 
contribute to coronary vasculogenesis. However, little is known about how coronary 
vessels ultimately form arterial and venous connections to the circulatory system. 
Semaphorin 3d (Sema3d) is a secreted guidance molecule that is required for proper 
connections of the pulmonary veins to the developing heart, but the receptor for Sema3d 
that mediates vascular patterning has not been defined. Although most secreted 
semaphorins bind to heterodimers of neuropilins and plexins, neuropilins can also 
interact with a variety of other partners to form functional receptors. Here, we show that 
Sema3d is necessary during embryogenesis not only for pulmonary vein development 
but also for proper connections of the coronary veins to the right side of the heart. We 
show, surprisingly, that ErbB2 is expressed by endothelial cells and can interact with 
neuropilin 1 (Nrp1) to form a functional Sema3d receptor to mediate repulsive guidance 
cues necessary for proper patterning of the coronary veins. These findings have 
implications for possible cardiovascular side-effects of anti-ErbB2 therapies and suggest 
new targets for pro- and anti-angiogenic strategies.  
 
Introduction 
	  
Early in mammalian development, circulating blood within the heart chambers is 
sufficient to provide oxygen and nutrients to the surrounding myocardium through simple 
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diffusion. As the embryo grows, increased demand is placed on the heart to pump blood 
to the body, and the myocardium thickens. The coronary vasculature develops to supply 
myocardial cells that can no longer be nutritionally sustained by simple diffusion from the 
cardiac lumen. Congenital abnormalities in coronary development can lead to 
pathologies such as myocardial ischemia, malignant arrhythmias, and sudden death 
(Angelini 2007).  
 
Blood vessels are patterned either by vasculogenesis, angiogenesis or a combination of 
the two processes. Vasculogenesis is the formation of blood vessels de novo from 
endothelial cells, while angiogenesis refers to the sprouting of new vessels from existing 
vessels. Until the late 1980s, it was believed that the coronary arteries and veins arose 
through angiogenesis from their points of origin, the aorta and coronary sinus 
respectively (Hutchins, Kessler-Hanna et al. 1988). That notion was challenged when it 
was shown that the coronary vasculature is present in the heart well before there are 
connections to the circulation (Bogers, Gittenberger-de Groot et al. 1989). Recently, a 
number of studies have identified various sources of the endothelial cells that give rise to 
the coronary arterial and venous vasculature including the proepicardium (Katz, Singh et 
al. 2012), epicardium, endocardium, and sinus venosus (Red-Horse, Ueno et al. 2010; 
Chen, Sharma et al. 2014). Cells migrating from these sources form tubular structures 
and a primary vascular plexus surrounding the heart. During this time, the arterial 
vascular tubes around the aortic trunk penetrate the aorta, while the venous capillary 
beds form connections with the coronary sinus allowing for circulation of blood through 
the coronary vessels. The coronary arteries receive oxygenated blood from the aorta 
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and the coronary veins return deoxygenated blood to the coronary sinus, which drains 
into the right atrium.  
 
Recent studies have revealed some clues to the cellular and molecular mechanisms 
required for coronary arterial connection to the aorta. Neural crest ablation in chick is 
associated with anomalous origins of the coronary arteries (Hood and Rosenquist 1992), 
and Vegf family ligands are necessary for coronary artery penetration into the aortic root 
(Tomanek, Ishii et al. 2006). However, very little, if anything, is known about the 
mechanisms mediating coronary venous connections. 
 
Class 3 semaphorins (Sema3) compose a family of secreted ligands that have been 
shown to be important guidance molecules in cardiovascular development and vascular 
patterning (Epstein, Aghajanian et al. 2015) in addition to their role in guiding neuronal 
path-finding (Dickson 2002). Sema3c deficient mice die perinatally from persistent 
truncus arteriosus and interrupted aortic arch (Feiner, Webber et al. 2001), Sema3e 
disruption leads to a loss of patterning of intersomitic vessels (Gu, Yoshida et al. 2005), 
and Sema3d null mice develop total anomalous pulmonary venous connections 
(TAPVC)(Degenhardt, Singh et al. 2013). Although Sema3e can bind to and signal via 
plexin D1 alone (Gu, Yoshida et al. 2005), most Sema3 proteins require the co-receptor 
neuropilin 1 (Nrp1) or neuropilin 2 to bind in conjunction with a signaling receptor such 
as a plexin (Takahashi, Fournier et al. 1999). Neuropilins are also known to 
heterodimerize with various related tyrosine kinase receptors such as Vegfr2 
(KDR)(Soker, Miao et al. 2002). 
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Erb-b2 receptor tyrosine kinase 2 (ErbB2) is a member of the epidermal growth factor 
(EGF) receptor family. ErbB2 is unique among EGF receptors in that it has no known 
direct ligand and generally functions as a co-receptor (Klapper, Glathe et al. 1999). 
Though ErbB2 expression is well characterized in myocardium (Wadugu and Kuhn 
2012) and plays a critical role in cardiac development (Crone, Zhao et al. 2002; Ozcelik, 
Erdmann et al. 2002), a role in endothelial function has yet to be described.  
 
In this chapter I demonstrate that Sema3d in the mouse is required for proper 
connections of the forming coronary veins to the right atrium and we provide evidence 
that it repels venous coronary endothelial cells during development to prevent 
anomalous venous connections to the left atrium. I show that ErbB2 interacts with Nrp1 
to form a Sema3d co-receptor expressed by developing coronary endothelium. Thus, 
ErbB2 plays an unexpected and important role in the vasculature. 
 
Results 
Abnormal coronary venous connections in Sema3d null mice 
We examined the hearts of postnatal Sema3d-/- mice to investigate the effects of 
Sema3d on the development of the coronary vasculature. Unlike human, murine 
coronary vessels reside in two distinct anatomical compartments. The coronary veins 
are subepicardial and are visible on the heart surface, while the coronary arteries are 
intramyocardial and cannot be visualized upon gross inspection. Surface vessels, the 
presumptive coronary veins, are seen abnormally connecting to the left atrium in 
Sema3d-/- adult hearts, but not in Sema3d+/- controls (Figure 4.1a). To better visualize 
the coronary vessels and connections, we perfused the vasculature with a low viscosity 
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compound (Microfil) and observed that ~30% of the Sema3d-/- hearts (8/27) displayed 
abnormal connections of the anterior interventricular vein (AIV) to the left atrium, while 
none (0/36) of the Sema3d+/- controls exhibited this abnormal connection (Figure 4.1b).  
 
To verify the arterial/venous identities of the coronary vessels, we crossed the Sema3d+/- 
mice with either an arterial (ephrin-B2LacZ) or venous (Ephb4LacZ) endothelial reporter. 
Whole-mount X-gal staining of Sema3d-/-;Ephb4LacZ/+ hearts shows Ephb4 positive 
vessels abnormally connecting to the left atrium (Figure 4.1c, arrow). These 
connections are absent in the Sema3d+/-;Ephb4LacZ/+ controls (Figure 4.1c). Arterial 
Microfil perfusion reveals normal origins of the coronary arteries in both Sema3d null and 
control hearts (Figure 4.1d). X-gal staining of Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/-
;ephrin-B2LacZ/+ hearts confirms the arterial identity of these coronary vessels (Figure 
4.1e). These data suggest that Sema3d specifically affects the connections of the 
coronary veins and not coronary arteries.  
 
We examined hearts from a developmental series of Sema3d-/-;Ephb4LacZ/+ and Sema3d-
/-;ephrin-B2LacZ/+ embryos, and litter mate controls, to determine if the initial formation of 
coronary vessels was perturbed. These experiments indicate that emergence of Ephb4+ 
venous coronary endothelium and assembly of the primitive vascular plexus that 
matures into the coronary venous system is unaffected by the absence of Sema3d, and 
the first reproducible defect that we observed was an abnormal connection to the left 
atrium evident by E15.5 (Figure 4.2). No clear abnormalities of arterial endothelial 
specification, plexus formation or connections with the aorta were identified (Figure 4.3). 
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In order to further examine the nature of the abnormal venous connections, we 
examined serial H&E stained sections, which confirmed the existence of an abnormal 
coronary vascular connection to the left atrium in Sema3d-/- hearts. The abnormal vessel 
is superficial, consistent with venous identity, and traverses the left anterior 
atrioventricular (AV) groove before emptying into the left atrial lumen (Figure 4.1f). X-gal 
and eosin stained serial sections from a Sema3d-/-;Ephb4LacZ/+ heart confirm the venous 
identity of this mis-patterned vessel (Figure 4.1g). 
 
Sema3d expression restricts coronary endothelium 
We further examined venous endothelial patterning at E15.5 when vascular defects were 
first detected in the Sema3d null hearts. X-gal staining of E15.5 Sema3d+/-;Ephb4LacZ/+ 
heart sections reveals little to no venous endothelium in the left anterior AV groove 
(Figure 4.4a). This is in contrast to numerous LacZ positive venous endothelial cells 
seen traversing this junction and in close association with the left atrium in Sema3d-/-
;Ephb4LacZ/+ embryonic hearts (Figure 4.4b). Examination of Sema3dGFPCre/+ hearts, 
which have GFP knocked into the Sema3d locus resulting in a null allele(Katz, Singh et 
al. 2012; Degenhardt, Singh et al. 2013), reveals that Sema3d is expressed within the 
left anterior AV groove (Figure 4.4c, arrow). In control embryos, this area of Sema3d 
expression is relatively avascular compared with the surrounding myocardium as 
determined by a lack of eNOS expression (Figure 4.4c). GFP is similarly expressed in 
the left anterior AV groove of the Sema3dGFPCre/GFPCre null hearts (Figure 4.4c, arrow), 
and lineage-tracing Sema3d expressing cells gives rise to a similar pattern of cells 
populating the AV groove in Sema3d null and control hearts (Figure 4.5). But unlike the 
controls, numerous eNOS positive vessels are seen penetrating this previously 
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avascular zone in Sema3dGFPCre/GFPCre (Figure 4.4d). Given the ability of Sema3d to 
function as an endothelial repellent (Aghajanian, Choi et al. 2014), we interpret these 
findings to suggest that Sema3d forms a barrier to restrict venous endothelial cells from 
populating the left anterior AV groove thereby preventing aberrant connections with the 
left atrium (Figure 4.4e). 
 
ErbB2 is a co-receptor for Sema3d 
Sema3d binds to and requires Nrp1 for signaling to endothelial cells (Degenhardt, Singh 
et al. 2013; Aghajanian, Choi et al. 2014), but a signaling co-receptor for Sema3d has 
yet to be fully described. To discover the endothelial signaling co-receptor for Sema3d 
we conducted a receptor tyrosine kinase screen (see methods) and identified ErbB2 as a 
potential Sema3d co-receptor. ErbB2 is phosphorylated in response to Sema3d in 
human umbilical vein endothelial cells (HUVECs) in a dose dependent manner (Figure 
4.6a). To determine the requirement of ErbB2 in Sema3d mediated endothelial guidance 
we employed a transwell migration assay. Both Sema3d and Sema3e are able to inhibit 
the migration of endothelial cells through a porous membrane (Figure 4.6b). Knockdown 
of ErbB2 specifically abrogates the ability of Sema3d, but not Sema3e, to inhibit 
endothelial migration (Figure 4.6b). We previously demonstrated Sema3d dependent 
phosphorylation of Akt and the requirement of PI3K/Akt signaling in Sema3d mediated 
endothelial guidance (Aghajanian, Choi et al. 2014). Akt and ErbB2 phosphorylation in 
response to Sema3d are both evident within 5 minutes of incubation (Figure 4.6c). 
siRNA knockdown of ErbB2 in HUVECs abrogates Sema3d-induced Akt phosphorylation 
(Figure 4.6d, e), indicating that ErbB2 is necessary for downstream repellent signaling 
mediated by Sema3d in HUVECs. 
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ErbB2 is expressed by coronary venous endothelial cells 
If ErbB2 is directly participating in Sema3d-mediated receptor signaling during coronary 
vein development, we predicted that it would be expressed by nascent coronary venous 
endothelium just prior to the time when abnormal venous connections are seen in 
Sema3d mutant embryos. At E14.5, shortly before anomalous venous connections are 
observed in Sema3d null hearts, eNOS-positive endothelial tubes co-express ErbB2 
(Figure 4.7a). Myocardial ErbB2 expression is also evident, consistent with previous 
observations of ErbB2 expression by cardiac muscle at earlier embryonic time-points 
(Lee, Simon et al. 1995) (Figure 4.7a). Expression of ErbB2 by coronary venous 
endothelium persists through at least E17.5 and is largely restricted in the heart to 
subepicardial (venous) endothelial cells (Figure 4.7b, Figure 4.8, white arrowheads) 
and not intra-myocardial (arterial) coronary vessels (Figure 4.7b, Figure 4.8, yellow 
arrowheads). At E14.5, Y1248 phosphorylation of ErbB2 is detected by 
immunofluorescence in coronary endothelium of Sema3d+/- hearts, consistent with 
receptor activation (Figure 4.7c). However, phospho-ErbB2 is not detected in coronary 
endothelium of Sema3d-/- hearts (Figure 4.7c). Importantly, genetic deletion of ErbB2 in 
endothelium during development, using Tie2-Cre, recapitulates the anomalous 
pulmonary venous connection (APVC) phenotype previously described in Sema3d-/- 
mice (Degenhardt, Singh et al. 2013)(Figure 4.9). Moreover, endothelial deletion of 
ErbB2 results in the anomalous coronary venous connection to the left atrium described 
here in Sema3d-/- mice (Figure 4.7d), providing strong genetic evidence for ErbB2 
functioning in a signaling pathway with Sema3d. 
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ErbB2 and Nrp1 form a Sema3d holoreceptor 
To test whether Sema3d is capable of directly binding to ErbB2, we performed binding 
experiments using an alkaline phosphatase (AP) tagged Sema3d (Sema3d-AP). 
Sema3d-AP does not bind to Cos-7 cells expressing ErbB2, but does bind to Nrp1 
expressing cells (Figure 4.10a). Co-expression of ErbB2 with Nrp1 does not increase 
the binding of Sema3d-AP over that seen with Nrp1 alone, suggesting that Nrp1 may 
serve to bind Sema3d while ErbB2 may participate in signal transduction (Figure 4.10a, 
Figure 4.11). Co-immunoprecipitation experiments indicate that ErbB2 and Nrp1 can 
physically interact in the presence or absence of Sema3d (Figure 4.10b). This 
interaction is validated by a proximity ligation assay, in which ErbB2 and Nrp1 are shown 
to be in close physical proximity (<40 nm) when co-transfected in 293T cells (Fig 4.12). 
Deletion of the extracellular domain of ErbB2 abolishes the interaction with Nrp1, while 
deletion of the intracellular domain of ErbB2 does not (Figure 4.10c). Serial truncations 
of the ErbB2 extracellular domain maps the Nrp1 interaction proximal to the 
transmembrane domain (Figure 4.13).  
 
siRNA-mediated knockdown of Nrp1 in HUVECs prevents ErbB2 receptor 
phosphorylation in response to Sema3d (Figure 4.10d), and ErbB2 and Nrp1 co-localize 
in coronary vessels of the developing heart (Figure 4.10e). Taken together, these data 
support the hypothesis that ErbB2 and Nrp1 heterodimerize to form a functional Sema3d 
holoreceptor.  
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Discussion 
 
In this study, we provide evidence for an unexpected role for ErbB2 in venous 
endothelial cells where it can partner with Nrp1 to form a receptor for the repellent 
guidance molecule Sema3d (Figure 4.10f). To the best of our knowledge, a functional 
role for ErbB2 in endothelium has not been previously reported, and these findings raise 
the possibility that vascular effects could arise from pharmacologic or other therapeutic 
approaches targeting ErbB2.  
 
ErbB2 is known to partner with various co-receptors including the epidermal growth 
factor receptor (EGFR), ErbB3 and ErbB4 (Tzahar, Waterman et al. 1996). Interestingly, 
ErbB2 has been previously implicated in semaphorin signaling. Certain class 4 
semaphorins involve ErbB2 in axonal growth cone collapse (Swiercz, Worzfeld et al. 
2009) or mitotic spindle orientation (Xia, Swiercz et al. 2015). A cleaved, oncogenic 
isoform of Sema3e signals through ErbB2 to promote metastasis (Casazza, Kigel et al. 
2012). In these examples, signaling requires a plexin in the receptor complex; plexin B1 
in the case of Sema4 proteins and plexin D1 in the case of Sema3e. A functional 
interaction between ErbB2 and Nrp1 has not been previously reported. 
 
In the heart, ErbB2 has been shown to play a critical role in development of the 
myocardium and has been implicated in control of cardiomyocyte proliferation (D'Uva, 
Aharonov et al. 2015) and as a potential target for regenerative therapies (Polizzotti, 
Ganapathy et al. 2015). Genetic deletion of ErbB2 in cardiomyocytes during 
development results in dilated cardiomyopathy (Crone, Zhao et al. 2002; Ozcelik, 
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Erdmann et al. 2002). Anticancer drugs targeting ErbB2 can lead to heart failure 
(Sengupta, Northfelt et al. 2008), presumably through cardiotoxicity. The coronary 
endothelial expression of ErbB2 that we describe here suggests an alternative 
mechanism to explain the cardiotoxic effects of such therapies. Perhaps inhibition of 
ErbB2 in endothelial cells results in endothelial dysfunction and secondary myocardial 
dysfunction. Further investigation of the role of ErbB2 in adult coronary endothelium will 
be required to address this hypothesis. 
 
Our results indicate that Sema3d is necessary for proper coronary venous connections 
in the developing heart, but is dispensable for coronary arterial connections. While there 
is evidence of the molecular determinants of coronary venous origin and development 
(Arita, Nakaoka et al. 2014), far less is known about the mechanisms of coronary venous 
connections. Based on the expression pattern of Sema3d, aberrant endothelial cell 
localization in Sema3d nulls, and the known repellent properties of Sema3d on 
endothelium, we propose that Sema3d expression in the left AV groove functions as a 
repellent barrier to prevent the developing coronary veins from aberrantly connecting to 
the left atrium. 
 
The clinical implications of abnormal venous patterning are generally less significant 
than those related to aberrations of arterial patterning, and this may explain why 
development of the coronary arteries has been more extensively studied than that of the 
coronary veins. Nevertheless, numerous variations of human coronary vein anatomy 
have been described (von Ludinghausen 1987; Loukas, Bilinsky et al. 2009) including 
anomalous connections to the left atrium (Pizarro, Castillo et al. 2009) as seen in 
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Sema3d null mice. The anatomy of the coronary veins is of clinical significance with 
regard to cardiovascular interventions such as cardiac pacing, retrograde cardioplegia 
during cardiopulmonary bypass (Ruengsakulrach and Buxton 2001), and interpretation 
of cardiac catheterization studies. There has also been recent evidence that the 
coronary veins instruct sympathetic innervation in the developing heart (Nam, Onitsuka 
et al. 2013).  
 
 
Materials and Methods 
 
Mice: 
All mice were maintained on a mixed genetic background. Sema3dGFPCre, Tie2-Cre, and 
R26Tomato alleles have been previously described (Kisanuki, Hammer et al. 2001; 
Madisen, Zwingman et al. 2010; Degenhardt, Singh et al. 2013). Ephb4LacZ/+ and ephrin-
B2LacZ/+ mice were obtained from the laboratory of Yoh-suke Mukouyama (NIH). 
ErbB2fl/LacZ hearts were obtained from the laboratory of Dr. Eldad Tzahor(Britsch, Li et al. 
1998; D'Uva, Aharonov et al. 2015) (Weizmann Institute of science). All animal protocols 
were approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee (IACUC).  
 
Reagents and antibodies: 
Human recombinant Sema3e (#3239-S3-025), human recombinant Sema3d were 
obtained from R&D Systems. Anti-phospho- Akt (#4060), anti-Akt (#9272), anti-β-actin 
(#4967), anti-ErbB2 (#4290), and anti-phospho-ErbB2 (#2247) were purchased from Cell 
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Signaling, along with anti-Nrp (Santa Cruz, #7239), anti-V5 (Life technologies, #R960), 
anti-ENOS (BD Biosciences, #610296), and anti-GFP (Abcam, #AB6673). Lipofectamine 
2000 (Invitrogen) was used as the transfection reagent for HEK293T and Cos-7 cells. 
Lipofectamine RNAiMAX (Invitrogen, 13778030) was used for siRNA transfections.  
 
Histology, immunohistochemistry, and whole-mount staining: 
Samples were harvested, fixed overnight in 2-4% paraformaldehyde and dehydrated 
through an ethanol series. All samples were paraffin-embedded and sectioned. 
Antibodies used for immunofluorescence were anti-ErbB2 (Cell Signaling), anti-phoshpo-
ErbB2 Y1248 (Cell Signaling), anti-Nrp1 (Santa Cruz), anti-GFP (Abcam), and anti-
eNOS (BD Biosciences). Hematoxylin and eosin (H&E) staining was completed using a 
standard protocol. 
 
For whole mount X-gal staining, adult and embryonic hearts were isolated and fixed with 
2% paraformaldehyde in PBS for 20 minutes at 4°C. Following fixation, the samples 
were washed twice for 10 minutes in PBS at 4°C. Embryos were stained in with PBS 
containing 1 mg/ml X-gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2, 0.01% NP-
40, 0.01% sodium deoxycholate and incubated overnight at 37 °C. 
 
Cell culture: 
Cos-7 and HEK293T cells were cultured in Dubeccoʼs modified Eagleʼs media (DMEM) 
from Sigma with 10% fetal bovine serum (FBS). Primary human umbilical vascular 
endothelial cells (HUVECs) (lot #1023) were cultured in human endothelial cell culture 
media, VascuLife® EnGS (#LL-0002) (basal EnGS media, 0.2% EnGS, 5 ng/ml rh EGF, 
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50 µg/ml ascorbic acid, 10 mM L-glutamine, 1.0 µg/ml hydrocortisone hemisuccinate, 
0.75 U/ml heparin sulfate and 2%) from Lifeline Cell Technology.  
 
Microfil: 
Mice were sacrificed at 2-3 weeks of age to evaluate the coronary artery and vein 
morphology. Mice were euthanized by CO2 inhalation, and the thoracic cavity was 
opened surgically. The large branches from the aorta were ligated. The vasculature was 
flushed with normal saline containing heparin (200 U/ml) via a needle inserted into the 
descending aorta until heart became visibly blanched. The heart was then pressure-fixed 
with 2% paraformaldehyde. Paraformaldehyde was flushed from the heart in heparinized 
saline, and coronary vasculature was injected with a radiopaque silicone rubber 
compound (Microfil MV-122; Flow Tech, Carver, MA) solution prepared in a volume ratio 
of 1:1 of Microfil diluent with 5% curing agent. Once filling is complete, to prevent 
the Microfil leakage from the coronary vessels, the accessible major vascular exit points 
were ligated immediately after filling. Heart was stored at 4 °C for contrast agent 
polymerization. 
 
Transwell migration assay: 
Triplicate transwell inserts (BD Biosciences, 353097) were coated on the underside with 
10µg/ml fibronectin (Roche, 11051407001) and placed in individual wells of a 24 well 
plate containing either 10nM recombinant Sema3d or vehicle (PBS) in DMEM. 
Endothelial cells treated with either an ErbB2 or control siRNA were trypsinized, re-
suspended in DMEM containing 0.2% BSA (Gemini, 700-101P) Cells were counted and 
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105 cells were seeded in each insert and allowed to migrate for 5 hours. The migrated 
cells were fixed in 4% paraformaldehyde for 2 mins, permeabilized in methanol for 20 
mins, and giemsa (Sigma, GS-500) stained for 25 mins. Cell that did not migrate were 
cleaned out from the inside of the insert with a cotton swab. Three high-power fields of 
each insert were imaged using an Olympus MVX10 microscope and quantified using 
ImageJ. 
 
Alkaline phosphatase binding assay: 
Alkaline phosphatase tagged Sema3d-AP (APtag5-Sema3d) was transfected into 
HEK293T cells to produce conditioned media. Sema3d-AP binding to transfected Cos7 
cells (YFP, plexin D1, Nrp1, ErbB2) was conducted as previously described(Gitler, Lu et 
al. 2004). Binding was visualized and recorded on an Olympus MVX10 microscope. 
Photomicrographs were analyzed and quantified using ImageJ software. 
  
Immunoprecipitation and Western blotting: 
Immunoprecipitation was performed by transfecting HEK293T cells with Nrp1 and/or 
ErbB2-V5, or truncated ErbB2 constructs. 48 hrs after transfection, cells were lysed with 
IP lysis buffer (50 mM Tris-HCl; 150 mM NaCl, 1% Ipegal (v/v)), and sonicated on ice. 
The cell lysates were precleared with protein-G dynabeads (Life technologies, #10004D) 
for 1 hr at 4°C. Precleared lysates were rotated with either 2 µg of Nrp1 antibody, or 2 µg 
of normal goat IgG (Santa Cruz, #2028) for 2 hrs at 4°C. Protein-G dynabeads were 
added and rotated overnight at 4°C. Beads were washed 3 times in IP wash solution (25 
mM Tris-HCl; 150 mM NaCl), eluted in sample buffer (Life technologies, #NP0007; 
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100nM DTT, 10% 2-mercaptoethanol), and run on a 4-12% Bis-Tris gradient gel (Life 
technologies, #NP0336). Gels were transferred to PVDF (Life technologies, #LC2002) 
and blocked according to antibody manufacturerʼs instructions. 
 
Blots were probed with anti-ErbB2 (1:1000), anti-phospho-ErbB2 (1:1000) anti-phospho-
Akt (1:2000), anti-Akt (1:1000), anti-β-actin (1:1000), anti-V5 (1:5000), or anti Nrp1 
(1:1000) as per manufacturerʼs instructions. Visualization was achieved using ECL Prime 
(GE Life Sciences, #RPN2232) exposed to autoradiography film (Denville, #E3018). 
Quantification of individual band intensity was performed using ImageJ. 
 
ErbB2 truncations: 
Truncations were made to the plasmid ErbB2-pEF-Dest51 using site directed 
mutagenesis PCR. PfuUltra high-fidelity DNA polymerase (Agilent, 600380) was used to 
amplify a plasmid with 5ʼ phosphorylated primers flanking the regions to be deleted 
(Primers available upon request). Linear PCR products were circularized using T4 DNA 
ligase (Invitrogen, 15224) and sequenced.  
 
RNA interference: 
HUVECs were transfected with Lipofectamine RNAiMAX (Invitrogen, 13778030) using 
ErbB2 siRNA (Cell Signaling), Nrp1 pre-designed siRNA (Ambion, #4914) or Silencer 
Negative control siRNA #1 (Ambion, AM4611) in antibiotic-free media. The media was 
changed to complete HUVEC media after 24 hrs, and the cells were used at 48 hrs. 
 
Proximity ligation assay: 
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HEK293T cells were grown in chamber slides (BD Falcon, Franklin Lakes, NJ) and 
transfected with 40ng of cDNA for ErbB2-V5 and/or WT Nrp1. All wells were incubated 
with a combination of anti-V5 (1:200) and anti-Nrp1 (1:200) primary antibodies for 1 
hour. Fluorescent visualization of interactions was performed using the Duolink® In Situ 
Detection Reagents- Red kit (Sigma-Aldrich, St. Louis, MO) following manufacturer's 
instructions. The Duolink® mounting media used includes DAPI nuclear stain. 
 
Receptor tyrosine kinase array: 
Receptor screening was performed using Proteome Profiler™ Human Phospho-RTK 
Array Kit (R&D Systems, ARY001B) per manufacturerʼs instructions. Briefly, HUVECs 
were incubated with either 10nM Sema3d or a PBS vehicle control for 30 minutes. Cells 
were washed and lysates were made using included lysis buffer plus protease inhibitors. 
The provided membranes were incubated with Sema3d treated and control cell lysates 
overnight at 4°C and probed with the provided Anti-Phospho-Tyrosine-HRP Detection 
Antibody. Membranes were incubated with a provided chemiluminescent reagent and 
exposed to autoradiography film (Denville, #E3018). Quantification of dot intensity was 
performed with ImageJ software. 
 
Statistics: 
All data are represented as the mean ± standard error of the mean (SEM). Two sets of 
data were compared using Studentʼs t-test. Differences between groups were compared 
with one-way analysis of variance (ANOVA). Significant ANOVA results were further 
analyzed by Tukeyʼs multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ns = 
not significant.   
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Figure 4.1 Coronary veins abnormally connect to the left atrium in Sema3d-/- 
hearts 
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Figure 4.1 Coronary veins abnormally connect to the left atrium in Sema3d-/- 
hearts.  
(a) Left anterior oblique view of adult Sema3d+/– (top) and Sema3d–/– (bottom) hearts. 
The anterior interventricular vein (arrow) can be seen connecting to the left atrium in the 
Sema3d-/- heart. (b) Mircrofil perfusion of 3 week old hearts from Sema3d+/– (top) and 
Sema3d–/– (bottom) mice. (c) Whole-mount X-gal staining of Sema3d+/-;Ephb4LacZ/+ (top) 
and Sema3d-/-;Ephb4LacZ/+ (bottom) postnatal hearts. (d) Cleared Sema3d+/– (top) and 
Sema3d–/– (bottom) postnatal hearts perfused with Microfil to visualize the origin of the 
coronary arteries (arrowheads). (e) Whole mount X-gal staining of Sema3d+/-;ephrin-
B2LacZ/+ (top) and Sema3d-/-;ephrin-B2LacZ/+ (bottom) postnatal hearts verifying arterial 
identity of the coronary vessels originating from the aorta (arrowheads). (f) 
Photomicrographs of H&E stained frontal sections from a Sema3d-/- heart following a 
coronary vein (arrows) from the left anterior AV groove connecting with the left atrial 
lumen. (g) Photomicrographs of eosin and X-gal stained frontal sections from a postnatal 
Sema3d-/-;Ephb4LacZ/+ heart following a coronary vein (arrows) from the left anterior AV 
groove connecting with the left atrial lumen. LV, left ventricle; RV, right ventricle; LA, left 
atrium; AO, aorta; PA, pulmonary artery. Scale bars = 100μm. 
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Figure 4.2 Whole mount X-gal staining on a developmental time-course of hearts 
from Sema3d+/-;Ephb4LacZ/+ and Sema3d-/-;Ephb4LacZ/+ embryos 
 
  
	   	   125	   	   	  
	  
Figure 4.2 Whole mount X-gal staining on a developmental time-course of hearts 
from Sema3d+/-;Ephb4LacZ/+ and Sema3d-/-;Ephb4LacZ/+ embryos.  
In both the Sema3d nulls and controls, Ephb4 expression can be seen as early as E10.5 
in the sinus venosus (a, j; arrows). Ephb4 positive endothelial cells are not seen (b-d, k-
m) outside of the immediate area surrounding the sinus venosus until E14.5 when the 
subepicardial endothelial cells re-specify to a venous identity, and are seen in both the 
Sema3d null and control hearts beginning at E14.5 (e, n; inset, arrowheads). By E15.5 
more mature venous vessels are present in the control and Sema3d null hearts (f, o; 
inset, arrowheads), and can be seen near the left atrium (o; arrow, inset).  One day 
later (E16.5), the anomalous connections of the coronary veins are grossly 
distinguishable in the nulls (p; arrow, inset) and continue to develop through gestation 
(q, r; arrows), but are not seen in the controls (g-i).  These data indicate that early in 
development Sema3d null venous endothelial cells migrate and pattern appropriately but 
by E15.5 incorrect venous connections begin to form. Scale bars = 100μm. 
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Figure 4.3 Whole mount X-gal staining on a developmental time-course of hearts 
from Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/-;ephrin-B2LacZ/+ embryos 
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Figure 4.3 Whole mount X-gal staining on a developmental time-course of hearts from 
Sema3d+/-;ephrin-B2LacZ/+ and Sema3d-/-;ephrin-B2LacZ/+ embryos. Ephrin-B2 positive 
arterial endothelial cells are not detected (a-b, j-k) until E12.5 when a peritruncal 
vascular plexus is seen (c, l; arrowheads, insets) in the Sema3d control and null 
hearts. Arterial development continues normally in the Sema3d null and control hearts 
(d-h, m-q) including the origins of the coronary arteries (i, r) at E18.5. Scale bars = 
100μm. 
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Figure 4.4 Sema3d expression excludes endothelium from the AV groove 
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Figure 4.4 Sema3d expression excludes endothelium from the AV groove.  
(a,b) X-gal and eosin staining of Sema3dGFPCre/+;Ephb4LacZ/+ (a) and 
Sema3dGFPCre/GFPCre;Ephb4LacZ/+ (b) E15.5 heart frontal sections. Numerous LacZ positive 
(venous) cells can be observed in the left anterior AV junction of the Sema3d nulls (b; 
arrow) but not in the control (a). (c,d) Immunofluorescence for the endothelial marker 
eNOS (red) and GFP (green) of E15.5 Sema3dGFPCre/+;Ephb4LacZ/+ (c) and 
Sema3dGFPCre/GFPCre;Ephb4LacZ/+ (d) heart frontal sections. The GFP expressing left 
anterior AV groove (arrow) is mostly avascular in the control (c) but penetrated by 
numerous eNOS positive (red) vessels in the Sema3d null (d). (e) Model depicting the 
role of Sema3d in coronary venous connection. In wild type mice, Sema3d is expressed 
in the left anterior AV groove and repels venous endothelium from abnormally forming 
connections with the left atrium (left), but in the absence of Sema3d the coronary 
anterior interventricular vein (AIV) abnormally connects to the LV (right). LV, left 
ventricle; RV, right ventricle; LA, left atrium; RA, right atrium. Scale bars = 100μm. 
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Figure 4.5 Sema3d fate-maps to left anterior AV groove 
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Figure 4.5 Sema3d fate-maps to left anterior AV groove. 
(a, b) Immunofluorescence for RFP (red) on frontal sections of E14.5 Sema3dGFPCre/+; 
R26Tomato/+ (a) and Sema3dGFPCre/GFPCre; R26Tomato/+ (b) hearts. Sema3d expressing cells 
similarly fatemap to the left anterior AV groove in both the control (a, outline) and null 
(b, outline) hearts. LA = Left atrium, LV = Left ventricle. Scale bars = 100μm. 
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Figure 4.6 Sema3d signals via ErbB2 in endothelial cells 
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Figure 4.6 Sema3d signals via ErbB2 in endothelial cells.  
(a) Western blot for phospho-ErbB2 (Y1248) from HUVECs incubated with increasing 
concentrations of Sema3d for 30 minutes. (b) Transwell migration assay showing the 
percentage HUVECs that migrated through a porous membrane in the presence of 
Sema3d or Sema3e when compared to vehicle control in the presence of a control 
siRNA (left) or ErbB2 siRNA (right). ***P < 0.001, *P < 0.05, ns = not significant (one-
way ANOVA between groups P < 0.001 for both groups; post-hoc multiple comparisons, 
Tukeyʼs test) (c) Western blot for phospho-Akt (S473) and phospho-ErbB2 (Y1248) from 
HUVECs incubated with increasing concentrations of Sema3d for 5 minutes. (d) Western 
blot for ErbB2 and phospho-Akt (S473) of HUVECs in the presence of control or ErbB2 
siRNA treated with Sema3d (10nM) for 5 minutes. (e) Quantification of ErbB2 
knockdown and Akt phosphorylation from (d). **P < 0.01, *P < 0.05 (Studentʼs t-test, 
n=3) 
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Figure 4.7 ErbB2 is expressed by coronary venous endothelium 
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Figure 4.7 ErbB2 is expressed by coronary venous endothelium.  
(a) Immunofluorescence of a frontal section of an E14.5 heart for the endothelial marker 
eNOS (red) and ErbB2 (green). ErbB2 and eNOS co-localize to vessels in the 
antrioventricular junction (arrowheads) (b) Frontal section of an E17.5 heart co-stained 
for eNOS (red) and ErbB2 (green) demonstrating co-localization in subepicardial vessels 
(white arrowheads) but not in intra-myocardial vessels (yellow arrowheads). (c) 
Phospho-ErbB2 (Y1248) immunofluorescence from frontal sections of E14.5 Sema3d+/– 
and Sema3d–/–hearts. ErbB2 phosphorylation is reduced in the Sema3d–/– hearts 
(arrowheads) (d) Photomicrographs of H&E stained frontal sections from a postnatal 
ErbB2fl/–;Tie2-Cre heart tracing a vessel from the left anterior AV groove to the left atrial 
lumen (arrows). LV, left ventricle; LA, left atrium. Scale bars = 100μm. 	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Figure 4.8 ErbB2 is specifically expressed in coronary venous endothelium 
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Figure 4.8 ErbB2 is specifically expressed in coronary venous endothelium. 
Immunofluorescence for the endothelial marker eNOS (red) and ErbB2 (green) on frontal 
sections from E17.5 heats showing the left ventricular wall. Subepicardial vessels 
(venous) are ErbB2 positive (yellow arrowheads), while deeper, myocardia vessels 
(arterial) are negative for ErbB2. Scale bars = 100μm. 
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Figure 4.9 ErbB2 endothelial loss results in APVC 
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Figure 4.9 ErbB2 endothelial loss results in APVC. 
(a-d) H&E stained cross sections of a postnatal ErbB2fl/-;Tie2-Cre heart. The pulmonary 
veins (green arrowhead) abnormally connect to the right atrium (RA) (d) resulting in an 
anomalous pulmonary connection (APVC). RA = Right atrium, LA = Left atrium, RV = 
Right ventricle, LV = Left ventricle, AO = Aorta, PA = Pulmonary artery, CS = Coronary 
sinus. Scale bars = 100μm. 
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Figure 4.10 ErbB2 and Nrp1 interact to form a Sema3d receptor 
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Figure 4.10 ErbB2 and Nrp1 interact to form a Sema3d receptor. 
(a) Representative photomicrographs of Cos-7 cells expressing indicated receptors after 
binding and enzymatic detection of alkaline phosphatase tagged Sema3d protein. (b) 
Co-immunoprecipitation of Nrp1 and ErbB2 in the presence or absence of Sema3d 
(10nM). (c) Graphical representation of ErbB2 deletion constructs (top). Co-
immunoprecipitation of Nrp1 and either full length or truncated ErbB2. (d) Western blot 
for phospho-ErbB2 (Y1248) from HUVECs treated with a Nrp1 or control siRNA, with or 
without Sema3d for 5 minutes. (e) Immunofluorescence of E15.5 hearts shows that 
ErbB2 (green) and Nrp1 (red) co-localize in coronary vessels. (f) Model for Sema3d 
signaling to coronary endothelial cells. Sema3d binds to the Nrp1 subunit of a 
Nrp1/ErbB2 complex on endothelial cells. This results in the phosphorylation and 
activation of ErbB2 and subsequent downstream signaling, including phosphorylation of 
Akt. ECD = extracellular domain, TM = transmembrane domain, ICD = intracellular 
domain. Scale bars = 10μm. 
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Figure 4.11 Quantification of Sema3d binding 
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Figure 4.11 Quantification of Sema3d binding. 
Quantification of the relative integrated density of Cos-7 cells expressing either a YPF 
control, plexin D1, ErbB2, Nrp1, or ErbB2 and Nrp1 bound with alkaline phosphatase 
(AP) tagged Sema3d (Sema3d-AP) and developed using an AP colorimetric assay. ***P 
< 0.001, ns = not significant. (one-way ANOVA between groups P < 0.001; post-hoc 
multiple comparisons, Tukeyʼs test) 
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Figure 4.12 ErbB2 and Nrp1 are expressed in close proximity 
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Figure 4.12 ErbB2 and Nrp1 are expressed in close proximity. 
Duolink proximity ligation assay (PLA) of 293T cells transfected with ErbB2-V5, Nrp1, or 
both. Red signal indicates physical proximity of proteins (<40 nm) and can be seen in the 
cells that were co-transfected with ErbB2-V5 and Nrp1 (arrowheads), but not in the 
controls. All conditions were incubated with anti-V5 and anti-Nrp1 antibodies. Scale bars 
= 100μm. 
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Figure 4.13 Graphical representation of ErbB2 truncations 
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Figure 4.13 Graphical representation of ErbB2 truncations.  
Co-immunoprecipitation of Nrp1 with either a full length (ErbB2-V5), progressive ErbB2 
extracellular truncation (T1-T3), or complete extracellular truncation (ErbB2-V5 ΔECD) 
protein. The shortest truncation of ErbB2 (T3) still interacts with Nrp1, while a complete 
loss of the extracellular domain completely abrogates this interaction. 
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Chapter 5 : Conclusions, Ongoing Work, and Future Directions 
 
Summary 
 
In this dissertation I explore the complex signaling molecules and pathways involved in 
patterning the vascular during development and how improper vascular patterning 
results in congenital heart defects. Deciphering the causes and mechanisms of 
congenital heart defects is a critical step in the process of one day developing novel 
therapies and cures.  
 
Chapter 2 began with the novel observation that mice null for Sema3d develop 
anomalous pulmonary venous connections (APVC). Using these mice as a model and 
tool to investigate APVC, we were able to demonstrate that the conventional 
assumptions regarding the etiology and morphogenesis of this disorder were incorrect 
and proposed a new way in which we believe APVC comes about. The role of Sema3d 
in this process is one of a repellent guidance molecule for endothelial cells that restricts 
the nascent pulmonary vein from forming abnormal connections. Sema3d binds and 
signals through the co-receptor neuropilin 1 to repel endothelial cells. Luckily we were 
able to obtain samples from and sequence the genome from patients with APVC and 
found at least 1 variant of Sema3d that had decreased binding and repellent activity in 
vitro, further suggesting an association.  
 
Continuing the investigations of the Sema3d mediated endothelial guidance that we 
observed in the work from Chapter 2; in Chapter 3 I explored the molecular cellular 
	   	   149	   	   	  
	  
effects of Sema3d on endothelial cells and compared and contrasted it with the class 3 
semaphorin Sema3e. Both Sema3d and Sema3e inhibit cell adhesion, motility, and 
migration by causing cytoskeletal reorganization. However, these effects are mediated 
by distinct molecular processes. Sema3e but not Sema3d requires the receptor plexin 
D1, while Sema3d but not Sema3e requires neuropilin 1. We find an additional molecular 
component in Sema3d signaling in that Sema3d requires PI3K/Akt signaling to exert its 
effects on endothelial cells. This is not the case with Sema3e.  
 
My work for Chapter 4 began with my ongoing pursuit to discover the signaling receptor 
for Sema3d. Through a receptor tyrosine kinase screen I found the RTK ErbB2 to be a 
possible receptor for Sema3d. We find that ErbB2 is phosphorylated by Sema3d 
incubation and required for Sema3d mediate repulsion of endothelial cells. Additionally 
ErbB2 is required for the Sema3d mediated Akt phosphorylation that I described in 
Chapter 3. In this investigation we found a second venous phenotype of the Sema3d 
nulls, abnormal connections of the coronary veins to the left atrium. Interestingly, we 
found that not only is ErbB2 expressed in the developing coronary vasculature, but 
conditional inactivation of ErbB2 in endothelial cells recapitulates the abnormal coronary 
venous phenotype of the Sema3d nulls and, strikingly, the APVC phenotype I described 
in Chapter 2. ErbB2 forms a complex with the co-receptor neuropilin 1, that I described 
in Chapters 2 and 3, to form a functional holoreceptor for Sema3d.  
 
In the next sections I will describe some of the ongoing projects that have come from 
investigating Sema3d and congenital heart defects, and also interesting future directions 
for pursuit.  
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Ongoing Work 
 
Endothelial Pdgfra 
In trying to dissect the signaling pathways necessary for Sema3d to properly pattern the 
vasculature, one of my main puzzles was discovering the signaling receptor or receptors 
involved. As I mentioned in the introductory chapter, I had hypothesized that platelet 
derived growth factor alpha (Pdgfra) was the signaling receptor for Semaphorin 3d. This 
was based on the genetic and animal model evidence showing an association of Pdgfra 
and the congenital heart disease total anomalous pulmonary venous connection 
(TAPVC), which we see in Sema3d null mice. Furthermore, our early experiments, 
outlined in Chapter 2, suggested that Sema3d was signaling directly to the developing 
endothelium and as such would require receptors on these endothelial cells to receive 
said signal. 
 
Pdgfra has been described in various cell types of the developing heart including cardiac 
neural crest, cardiomyocytes, smooth muscle, and epicardial cells. Surprisingly, Pdgfra 
expression had not been described in developing or adult endothelial cells. To 
investigate Pdgfra expression in the developing vasculature, I performed flow cytometry 
on cells from E11.5 Pdgfra-GFP embryos that were co-labeled with fluorescently 
conjugated antibodies against Pecam1 (an endothelial marker) and GFP. Based on the 
analysis from the flow cytometry, Pdgfra is expressed in up to 10% of the endothelial 
cells of the developing embryo (Figure 5.1). Once it was established that Pdgfra was 
expressed in embryonic endothelial cells, I sought to test the hypothesis that Pdgfra was 
a receptor for Sema3d in developing endothelium. To test this, I used genetic tools to 
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inactivate Pdgfra in endothelial cells. This was achieved this by crossing a Pdgfra floxed 
allele with a Tie2Cre to create a conditional inactivation of Pdgfra. Conditional 
inactivation of Pdgfra in the endothelium results in partial embryonic lethality (Table 5.1). 
Of the ones that made it to birth (2/90), none had anomalous pulmonary venous 
connections (data not shown). Furthermore, 7 additional mid-gestation Pdgfrafl/fl;Tie2-Cre 
embryos had normal connections of the pulmonary veins. These mutants displayed 
subtle cardiovascular abnormalities (hemorrhage, stenosis, clots), but no major heart 
defects were noted. 
 
To try to enhance the penetrance of an effect, we crossed the Pdgfra-flox allele onto a 
Pdgfra-null background to achieve haploinsufficiency. While Pdgfrafl/fl;Tie2-Cre mice 
again did not have anomalous connections of the pulmonary veins, we were surprised to 
find that some of these mutants developed transposition of the great arteries (TGA) 
(Figure 5.2). As I described earlier in the introductory chapter, TGA is a congenital heart 
defect where the aorta and the pulmonary artery fail to connect to the left ventricle and 
right ventricle respectively, instead are switched and the aorta connects to the right 
atrium and the pulmonary artery connects to the left atrium.  
 
Development of the outflow tract is dependent on proper formation of the endocardial 
cushions. The mesenchyme of the endocardial cushions is populated by endothelial cells 
that have undergone EMT and migrated into the cardiac jelly and neural crest cells that 
have migrated from the dorsal neural tube through the pharyngeal arches. We performed 
H&E staining on frontal sections of E11.5 embryos to assess the morphology of the 
outflow tract in Pdgfrafl/–;Tie2-Cre and control hearts. We find that the endocardial 
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cushions of the anterior outflow tract are hypocellular when compared to controls 
(Figure 5.3). At this point our data for investigating the cause of this is preliminary, but it 
does not seem like there is a defect in proliferation, apoptosis, or EMT (data not shown), 
but we must rigorously continue investigations in this regard to draw conclusions. To 
assess the possibility that the lack of cells in the endocardial cushions was due to 
improper neural crest migration, we performed in sutu hybridization of a probe for the 
neural crest marker plexin A2 (Plxna2) on E11.5 outflow tract sections. Interestingly, we 
find that there seems to be a defect or delay in neural crest migration in Pdgfrafl/–;Tie2-
Cre hearts when compared to control (Figure 5.4). 
 
There is much to do and many questions to answer in elucidating the causes of TGA in 
these mutants and the morphogenesis of this disorder. The defects in neural crest 
migration in these mutants are an interesting clue in the etiology of TGA, however this is 
probably not the whole story. While neural crest ablation and failure of neural crest to 
migrate to the outflow tract do result in outflow tract abnormalities such as PTA and 
DORV (Kirby and Waldo 1995), these deficiencies do not result in TGA. Further, is not 
clear if the hypocellular endocardial cushions are a cause of TGA or resultant from a 
separate process. It is interesting that the Pdgfrafl/–;Tie2-Cre develop TGA while the 
Pdgfrafl/fl;Tie2-Cre mice do not. While it is clear that Pdgfra in the endothelium is 
important in development, it does not seem to be completely necessary in outflow tract 
development. In the future it will be important to determine precise expression patterns 
and fate-maps of Pdgfra as well as Pdgf ligands during spatially and temporally critical 
points. While our investigations are still preliminary, the identification of Pdgfra in 
developmental endothelium and resulting TGA in Pdgfra mutants are important 
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observations and provide a new tool for investigating this congenital heart defect in the 
future.  
 
Future Directions 
 
My studies have largely focused on the role of Sema3d and its receptors ErbB2/Nrp1 in 
developmental venous endothelium. It will be of interest to determine if this signaling 
pathway plays functional roles in other types of endothelium during development and in 
the adult, and whether it also functions in other cell types including cancer cells. ErbB2, 
Nrp1, and semaphorins have all been implicated in various malignancies. Multiple 
classes of semaphorins have been shown to have both pro- and anti-cancer properties 
and are being investigated as therapeutic targets (Tamagnone 2012). ErbB2, also known 
as Her2, is an important therapeutic target in a subset of breast cancers (Yu and Hung 
2000). ErbB2 overexpression is also seen in gastric and lung cancers (Gravalos and 
Jimeno 2008; Grob, Kannengiesser et al. 2012). Similarly, Nrp1 overexpression in breast 
and lung cancer is associated with worse outcomes (Hong, Chen et al. 2007; Ghosh, 
Sullivan et al. 2008). In fact we find that ErbB2 and Nrp1 are co-expressed in a subset of 
tumor vessels in a mouse model of breast cancer (Figure 5.5). In exploring other cell 
types we find that ErbB2 and Nrp1 are also co-expressed in the actual tumor cells of 
Kras mediated lung tumors in mice (Figure 5.6a). Furthermore, I analyzed gene 
expression and survival data from the TCGA Research Network 
(http://cancergenome.nih.gov/) and found ErbB2 and Nrp1 expression positively 
correlated in lung cancer patients (Figure 5.6b), and those with high ErbB2 and high 
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Nrp1 expression had significantly worse overall survival than those with low levels of 
both (Figure 5.6c).  
 
One of the biggest successes in breast cancer treatment has been specifically targeting 
ErbB2 overexpressing cancers with the humanized monoclonal antibody trastuzumab 
(Herceptin, Genentech/Roche)(Hudis 2007). Herceptin works by binding to ErbB2 and 
inhibiting dimerization, signaling to intercellular molecules (Akt, Mapk), and/or proteolytic 
cleavage. Herceptin treatment increases both overall and disease free survival in 
patients with ErbB2 expressing breast cancers. One of the main problems with this 
treatment is that a majority of eligible (ErbB2 overexpressing) patients are initially 
resistant to Herceptin, and all patients eventually develop resistance (Vu and Claret 
2012).  
 
One model of Herceptin resistance involves expression of truncated ErbB2 fragments 
known as p95HER2 (Vu and Claret 2012). p95HER2 is a c-terminally truncated ErbB2 
fragment lacking most of the  extracellular domain, and in particular the Herceptin 
binding epitope. p95HER2 cancers are not able to be targeted by Herceptin and 
represent a subtype of ErbB2 expressing breast cancers with an even more aggressive 
phenotype. This truncated form also lacks the domain required for ErbB dimerization. 
Interestingly, even though p95HER2 lacks the domain required for dimerization to other 
ErbB members, as I demonstrated in Chapter 4, Nrp1 requires only a small fragment of 
the extracellular domain of ErbB2 to bind. It is possible that a p95HER2 complex exists 
in these cancers and may be a possible target for Herceptin resistant p95HER2 
truncations for therapy. 
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Finding ErbB2 expressed in tumor vasculature is interesting for a number of reasons. 
ErbB2 overexpression in tumor is associated with increased angiogenesis and 
vascularization (Kumar and Yarmand-Bagheri 2001). This the proposed reasons for this 
is that ErbB2 causes the expression of Vegf which in turn induces angiogenesis. Also, 
anti-ErbB2 therapies result in decreased angiogenesis supposedly by blocking the 
ErbB2-Vegf axis. The observation the ErbB2 is expressed in the endothelial cells of the 
tumor vasculature begs for the re-assessment of these hypotheses. Perhaps ErbB2 
plays a direct role in tumor endothelium and anti-ErbB2 therapies have and anti-
angiogenic effect by binding to endothelial cells. It will be important to know whether anti-
ErbB2 therapies block signaling of Sema3d, or if it through a separate pathway. We do 
not know any of these things for certain, but at this point warrants further investigation. 
 
Investigating ErbB2 in the adult vasculature may also be very interesting. The cardiotoxic 
effects of ErbB2 on the heart are well known (Ewer and Ewer 2015). It has been 
assumed that this is because of the targeting ErbB2 directly on the cardiomyocytes. 
While this may be the case, if ErbB2 is expressed in adult coronary endothelium like it is 
in developmental coronary endothelium, anti-ErbB2 therapies may be having a 
destructive role in the coronary vasculature that leads to the heart disease in patients 
treated with these therapeutics. In addition, it would be of interest to know what role, if 
any, these signaling pathways play in adult vascular remodeling and re-vascularization 
following injury. 
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To map the interaction domains of ErbB2 and Nrp1 we made serial truncations of the 
extracellular domain of ErbB2. We found that only a very small portion of the 
extracellular domain near the transmembrane site is required for this interaction. In the 
future I would like to do a similar series for Nrp1. The Nrp1 consists of 2 CUB domains 
(a1,a2; semaphorin binding domains), 2 FV/FVIII domains (b1,b2; Vegf binding 
domains), a MAM domain (c) responsible for oligomerization, a transmembrane domain, 
and a short intercellular domain that is not thought to signal. It is important to know 
where the interaction occurs to properly test its importance. We have not yet definitely 
proven that the interaction of ErbB2 and Nrp1 is responsible for the effects we have 
seen. To test this, we would need to specifically block the interaction while keeping other 
functions of these proteins intact. There are a few ways we can consider achieving this 
goal once we have a better understanding of the interacting domain/amino acids. One 
way would be to design a monoclonal antibody against the interacting region of one or 
both receptors. Incubation with this antibody could specifically block the interaction of 
these receptors, while leaving the overall expression, conformation, and alternate 
functions intact. We are lucky enough that the interaction takes place on the extracellular 
side of the receptor as it allows us to work with live cells. Another possible way would be 
to specifically mutate the few critical amino acids necessary for this interaction and 
perform in vitro experiments regarding semaphorin as well as other signaling pathways. 
For this approach to work, the other functions of the protein would have to remain intact 
There are a few caveats with this approach that can be addressed. First is that 
overexpression studies have their limitations with regards to gene dosage. This can 
potentially be counteracted with mutating the genomic locus, possibly by using CRISPR 
technology. Another caveat when mutating a protein is making sure that the protein is 
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processed and shuttled properly in the cell. This can be assessed with careful 
investigation. 
 
Concluding Remarks 
 
My course during my thesis work has been one of letting the science guide the path and 
following what is interesting. When I first began investigating the phenotype of the 
Sema3d mouse, I had no clue to the interesting and divergent paths that were in store 
for me. My first foray into identifying the signaling receptor for Sema3d led me to 
investigating Pdgfra, which turned out to have a completely unrelated but equally 
interesting cardiovascular phenotype. This led to a new mouse model for the congenital 
heart defect, transposition of the great arteries, and clues to the mechanisms involved in 
development of this disorder.  
 
My second attempt at identifying the signaling receptor for Sema3d led me to an unlikely 
receptor tyrosine kinase, more well known for its role in cancer than in congenital heart 
disease, ErbB2. Though it was indeed unlikely, and raised a lot of questions, the science 
kept supporting my hypothesis that Sema3d signaled through ErbB2 in endothelial cells. 
We were finally able to definitely test our hypothesis by modeling loss of ErbB2 in 
developing endothelium which recapitulated both the anomalous pulmonary venous 
connection phenotype of Sema3d nulls, but also the coronary vascular phenotype. 
Regarding the coronary venous connection abnormalities seen in the Sema3d null mice, 
this phenotype was discovered off-hand when investigating something unrelated in these 
mice. I did not know much of coronary patterning at the time, but was surprised to find 
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that nothing was know about connections of the coronary veins during development. 
Although the coronary veins do not garner as much interest as the coronary arteries, 
pursuing this interesting phenotype allowed me to connect more dots regarding Sema3d 
signaling to endothelial cells. This also led us to discover a novel binding partner for 
ErbB2 in neuropilin 1, and possibly a new way in which we can imagine ErbB signaling. 
 
From where we stand, science is again pointing us in interesting and exciting new 
directions. One takeaway I have from my experiences is that I believe that one must be 
willing to keep and open mind and try not to let our assumptions and biases restrict our 
investigations. With that in mind, I am excited to see where science will take us next.  
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Table 5.1 
 
 
Total – 90  
Chi-square – 27.6 
P – value – <0.001 
 
 
	    
Genotype Wt cre- Wt cre+ Het cre- Het cre+ fl/fl cre- fl/fl cre+ 
Observed 7 22 17 34 8 2 
Expected 11.25 11.25 22.5 22.5 11.25 11.25 
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Figure 5.1 Pdgfra is expressed in developmental endothelium 
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Figure 5.1 Pdgfra is expressed in developmental endothelium.  
Flow cytometry from whole embryo single cell suspensions of E11.5 PdgfraGFP/+ 
embryos using a no antibody control (a), CD31 antibody alone (b,c), GFP antibody alone 
(d,e) or a combination of both (f,g). Histograms represent the distribution of the blue 
square gates in each set. 
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Figure 5.2 Pdgfra mutants develop transposition of the great arteries. 
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Figure 5.2 Pdgfra mutants develop transposition of the great arteries.  
Gross anatomy and H&E stained sections of E17.5 and P0 hearts from and PdgfraGFP/flox 
(top row) and PdgfraGFP/flox;Tie2-Cre (bottom row). Transposition of the great arteries is 
seen in the Pdgfrafl/–;Tie2-Cre hearts but not in the controls. 
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Figure 5.3 Hypoplastic endocardial cushions in Pdgfra mutants 
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Figure 5.3 Hypoplastic endocardial cushions in Pdgfra mutants. 
H&E stained serial section of E11.5 Pdgfraflox/+ (top row) and PdgfraGFP/flox;Tie2-Cre 
(bottom row) hearts showing frontal and sagittal views of the outflow tract. Significant 
hypoplasia is evident in the anterior outflow tract of the PdgfraGFP/flox;Tie2-Cre hearts. 
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Figure 5.4 Neural crest migration is disturbed in Pdgfra mutants 
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Figure 5.4 Neural crest migration is disturbed in Pdgfra mutants. 
In situ hybridization of a probe for the neural crest marker plexin A2 on E11.5 Pdgfraflox/+ 
(top row) and PdgfraGFP/flox;Tie2-Cre (bottom row) hearts. Fewer plexin A2 positive neural 
crest cells are present in the endocardial cushions of the PdgfraGFP/flox;Tie2-Cre outflow 
tract (arrows). 
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Figure 5.5 ErbB2 and Nrp1 are co-expressed on endothelial cells in mammary 
tumors 
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Figure 5.5 ErbB2 and Nrp1 are co-expressed on endothelial cells in mammary 
tumors.  
Section from a mouse mammary tumor co-stained for Pecam1 (blue), ErbB2 (green), 
and Nrp1 (red).  
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Figure 5.6 ErbB2 and Nrp1 are co-expressed in lung tumors 
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Figure 5.6 ErbB2 and Nrp1 are co-expressed in lung tumors.  
(a) Section from a HopxER-Cre/+;K-RasG12D;R26mT-mG/+ lung tumor immunostained for ErbB2 
(green) and Nrp1 (red). (b) Correlation of ErbB2 and Nrp1 expression from 1130 patients 
with lung cancer. (c) Kaplan-Meier survival curve comparing lung cancer patient that 
express high levels of ErbB2 and Nrp1 (n=352) vs low levels of ErbB2 and Nrp1 
(n=339). Scale bars = 100μm 
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